[
    {
        "id": "1",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "2",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "3",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "35 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "4",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "5",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "6",
        "Proprietary Name": "ABSORICA",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "7",
        "Proprietary Name": "ACANYA",
        "Dosage Form": "Gel",
        "Strength": "1.2% / 2.5%",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "07/2018"
    },
    {
        "id": "8",
        "Proprietary Name": "ACCOLATE",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "AstraZeneca Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "11/19/2010"
    },
    {
        "id": "9",
        "Proprietary Name": "ACCOLATE",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "AstraZeneca Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "11/19/2010"
    },
    {
        "id": "10",
        "Proprietary Name": "ACEPHEN",
        "Dosage Form": "Suppositories",
        "Strength": "120 mg",
        "NDA Applicant Name": "G & W Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "11",
        "Proprietary Name": "ACETADOTE",
        "Dosage Form": "Injection",
        "Strength": "6 g/30 mL (200 mg/mL)",
        "NDA Applicant Name": "Cumberland Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "1/7/2013"
    },
    {
        "id": "12",
        "Proprietary Name": "ACTICLATE",
        "Dosage Form": "Tablets",
        "Strength": "75 mg",
        "NDA Applicant Name": "Almirall, LLC",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "13",
        "Proprietary Name": "ACTICLATE",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Almirall, LLC",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "14",
        "Proprietary Name": "ACTIGALL",
        "Dosage Form": "Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "08/13/2003"
    },
    {
        "id": "15",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "800 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "16",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "200 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "17",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "400 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "18",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "600 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "19",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "1200 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "20",
        "Proprietary Name": "ACTIQ",
        "Dosage Form": "Lozenge",
        "Strength": "1600 mcg",
        "NDA Applicant Name": "Cephalon, LLC",
        "Date Authorized Generic Entered the Market": "09/26/2006"
    },
    {
        "id": "21",
        "Proprietary Name": "ACTONEL",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Allergan Pharmaceuticals International Ltd.",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "22",
        "Proprietary Name": "ACULAR LS",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.4%",
        "NDA Applicant Name": "Allergan, Inc.",
        "Date Authorized Generic Entered the Market": "11/11/2013"
    },
    {
        "id": "23",
        "Proprietary Name": "ACZONE",
        "Dosage Form": "Gel",
        "Strength": "7.5%",
        "NDA Applicant Name": "Almirall, LLC",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "24",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "25",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "26",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "27",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "28",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "29",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "30",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "10/2016 - 10/2017"
    },
    {
        "id": "31",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "32",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "33",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "34",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "35",
        "Proprietary Name": "ADDERALL XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals USA Inc.",
        "Date Authorized Generic Entered the Market": "04/02/2009"
    },
    {
        "id": "36",
        "Proprietary Name": "ADRENACLICK",
        "Dosage Form": "Injection",
        "Strength": "0.3 mg",
        "NDA Applicant Name": "Impax Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2010"
    },
    {
        "id": "37",
        "Proprietary Name": "ADRENACLICK",
        "Dosage Form": "Injection",
        "Strength": "0.15 mg",
        "NDA Applicant Name": "Impax Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2010"
    },
    {
        "id": "38",
        "Proprietary Name": "ADVAIR DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "500/50 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "39",
        "Proprietary Name": "ADVAIR DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "250/50 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "40",
        "Proprietary Name": "ADVAIR DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "100/50 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "41",
        "Proprietary Name": "ADVAIR HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "230/21 MCG",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd. England",
        "Date Authorized Generic Entered the Market": "3/1/2023"
    },
    {
        "id": "42",
        "Proprietary Name": "ADVAIR HFA",
        "Dosage Form": "Inhalation Aresol",
        "Strength": "45/21 MCG",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd. England",
        "Date Authorized Generic Entered the Market": "3/1/2023"
    },
    {
        "id": "43",
        "Proprietary Name": "ADVAIR HFA",
        "Dosage Form": "Inhalation Aresol",
        "Strength": "115/21 MCG",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd. England",
        "Date Authorized Generic Entered the Market": "3/1/2023"
    },
    {
        "id": "44",
        "Proprietary Name": "AGGRASTAT",
        "Dosage Form": "Solution for Injection Premixed",
        "Strength": "0.25 mg/mL",
        "NDA Applicant Name": "Medicure International Inc.",
        "Date Authorized Generic Entered the Market": "3/2024"
    },
    {
        "id": "45",
        "Proprietary Name": "AIRDUO RESPICLICK",
        "Dosage Form": "Inhalation Powder",
        "Strength": "232 mcg / 14 mcg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D Inc.",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "46",
        "Proprietary Name": "AIRDUO RESPICLICK",
        "Dosage Form": "Inhalation Powder",
        "Strength": "113 mcg / 14 mcg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D Inc.",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "47",
        "Proprietary Name": "AIRDUO RESPICLICK",
        "Dosage Form": "Inhalation Powder",
        "Strength": "55 mcg / 14 mcg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D Inc.",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "48",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2020"
    },
    {
        "id": "49",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2020"
    },
    {
        "id": "50",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2012"
    },
    {
        "id": "51",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2014"
    },
    {
        "id": "52",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2014"
    },
    {
        "id": "53",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2014"
    },
    {
        "id": "54",
        "Proprietary Name": "ALAWAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.035%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "2020"
    },
    {
        "id": "55",
        "Proprietary Name": "ALDACTAZIDE",
        "Dosage Form": "Tablet",
        "Strength": "25 mg/25 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "12/01/2021"
    },
    {
        "id": "56",
        "Proprietary Name": "ALDACTAZIDE",
        "Dosage Form": "Tablets",
        "Strength": "25 mg/25 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "10/06/2003"
    },
    {
        "id": "57",
        "Proprietary Name": "ALINIA",
        "Dosage Form": "Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Romark Laboratories, L.C.",
        "Date Authorized Generic Entered the Market": "02/2021"
    },
    {
        "id": "58",
        "Proprietary Name": "ALLEGRA",
        "Dosage Form": "Tablets",
        "Strength": "30 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "02/2005 - 02/2006"
    },
    {
        "id": "59",
        "Proprietary Name": "ALLEGRA",
        "Dosage Form": "Tablets",
        "Strength": "60 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "02/2005 - 02/2006"
    },
    {
        "id": "60",
        "Proprietary Name": "ALLEGRA",
        "Dosage Form": "Tablets",
        "Strength": "180 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "02/2005 - 02/2006"
    },
    {
        "id": "61",
        "Proprietary Name": "ALLEGRA-D 12 HOUR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "60 mg/120 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "12/2004 - 12/2005"
    },
    {
        "id": "62",
        "Proprietary Name": "AMARYL",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "11/2004 - 11/2005"
    },
    {
        "id": "63",
        "Proprietary Name": "AMARYL",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "11/2004 - 11/2005"
    },
    {
        "id": "64",
        "Proprietary Name": "AMARYL",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "11/2004 - 11/2005"
    },
    {
        "id": "65",
        "Proprietary Name": "AMBIEN CR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "6.25 mg",
        "NDA Applicant Name": "Sanofi Aventis U.S. LLC",
        "Date Authorized Generic Entered the Market": "10/2010"
    },
    {
        "id": "66",
        "Proprietary Name": "AMBIEN CR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Sanofi Aventis U.S. LLC",
        "Date Authorized Generic Entered the Market": "12/2010"
    },
    {
        "id": "67",
        "Proprietary Name": "AMICAR",
        "Dosage Form": "Tablets",
        "Strength": "1000 mg",
        "NDA Applicant Name": "Clover Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "68",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsule",
        "Strength": "24 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas, LLC",
        "Date Authorized Generic Entered the Market": "1/1/2023"
    },
    {
        "id": "69",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsule",
        "Strength": "8 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas, LLC",
        "Date Authorized Generic Entered the Market": "1/1/2023"
    },
    {
        "id": "70",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsule",
        "Strength": "8 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas, LLC",
        "Date Authorized Generic Entered the Market": "1/1/2023"
    },
    {
        "id": "71",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsule",
        "Strength": "24 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas LLC",
        "Date Authorized Generic Entered the Market": "1/1/2023"
    },
    {
        "id": "72",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsules",
        "Strength": "24 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas, LLC",
        "Date Authorized Generic Entered the Market": "01/2021"
    },
    {
        "id": "73",
        "Proprietary Name": "AMITIZA",
        "Dosage Form": "Capsules",
        "Strength": "8 mcg",
        "NDA Applicant Name": "Sucampo Pharma Americas, LLC",
        "Date Authorized Generic Entered the Market": "01/2021"
    },
    {
        "id": "74",
        "Proprietary Name": "AMMONUL",
        "Dosage Form": "Injection",
        "Strength": "10% / 10%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/2017"
    },
    {
        "id": "75",
        "Proprietary Name": "AMPYRA",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Acorda Therapeutics, Inc.",
        "Date Authorized Generic Entered the Market": "09/2018"
    },
    {
        "id": "76",
        "Proprietary Name": "AMRIX",
        "Dosage Form": "Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "77",
        "Proprietary Name": "AMRIX",
        "Dosage Form": "Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "78",
        "Proprietary Name": "AMRIX",
        "Dosage Form": "Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "79",
        "Proprietary Name": "AMRIX",
        "Dosage Form": "Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "80",
        "Proprietary Name": "ANAFRANIL",
        "Dosage Form": "Capsules",
        "Strength": "75 mg",
        "NDA Applicant Name": "Mallinckrodt",
        "Date Authorized Generic Entered the Market": "07/2015"
    },
    {
        "id": "81",
        "Proprietary Name": "ANAFRANIL",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Mallinckrodt",
        "Date Authorized Generic Entered the Market": "07/2015"
    },
    {
        "id": "82",
        "Proprietary Name": "ANAFRANIL",
        "Dosage Form": "Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Mallinckrodt",
        "Date Authorized Generic Entered the Market": "07/2015"
    },
    {
        "id": "83",
        "Proprietary Name": "ANAPROX DS",
        "Dosage Form": "Tablets",
        "Strength": "550 mg",
        "NDA Applicant Name": "Atnahs Pharma US Limited",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "84",
        "Proprietary Name": "ANCOBAN",
        "Dosage Form": "Capsules",
        "Strength": "500 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "01/17/2012"
    },
    {
        "id": "85",
        "Proprietary Name": "ANCOBAN",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "86",
        "Proprietary Name": "ANGIOMAX",
        "Dosage Form": "Powder, for injection solution, lyophilized",
        "Strength": "250 mg",
        "NDA Applicant Name": "Sandoz Inc.",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "87",
        "Proprietary Name": "ANGIOMAX",
        "Dosage Form": "Powder, for injection solution, lyophilized",
        "Strength": "250 mg",
        "NDA Applicant Name": "Sandoz Inc.",
        "Date Authorized Generic Entered the Market": "02/2017"
    },
    {
        "id": "88",
        "Proprietary Name": "ANTARA",
        "Dosage Form": "Capsules",
        "Strength": "130 mg",
        "NDA Applicant Name": "Lupin, Inc.",
        "Date Authorized Generic Entered the Market": "02/22/2013"
    },
    {
        "id": "89",
        "Proprietary Name": "ANTARA",
        "Dosage Form": "Capsules",
        "Strength": "43 mg",
        "NDA Applicant Name": "Lupin, Inc.",
        "Date Authorized Generic Entered the Market": "02/22/2013"
    },
    {
        "id": "90",
        "Proprietary Name": "ANTIVERT",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "91",
        "Proprietary Name": "ANTIVERT",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "92",
        "Proprietary Name": "APADAZ",
        "Dosage Form": "Tablets",
        "Strength": "8.16 mg / 325 mg",
        "NDA Applicant Name": "KVK-Tech, Inc.",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "93",
        "Proprietary Name": "APRISO",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "0.375 g",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "07/19/2018"
    },
    {
        "id": "94",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "95",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "96",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "97",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "98",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "99",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "100",
        "Proprietary Name": "APTENSIO XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "101",
        "Proprietary Name": "ARAVA",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "09/07/2015"
    },
    {
        "id": "102",
        "Proprietary Name": "ARAVA",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "09/07/2015"
    },
    {
        "id": "103",
        "Proprietary Name": "ARICEPT",
        "Dosage Form": "Film coated tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Eisai, Inc.",
        "Date Authorized Generic Entered the Market": "11/25/2009 - 11/24/2010"
    },
    {
        "id": "104",
        "Proprietary Name": "ARICEPT",
        "Dosage Form": "Film coated tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Eisai, Inc.",
        "Date Authorized Generic Entered the Market": "11/25/2009 - 11/24/2010"
    },
    {
        "id": "105",
        "Proprietary Name": "ARICEPT ODT",
        "Dosage Form": "Orally disintegrating tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Eisai, Inc.",
        "Date Authorized Generic Entered the Market": "10/18/2009 - 11/24/2010"
    },
    {
        "id": "106",
        "Proprietary Name": "ARICEPT ODT",
        "Dosage Form": "Orally distinegrating tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Eisai, Inc.",
        "Date Authorized Generic Entered the Market": "10/18/2009 - 11/24/2010"
    },
    {
        "id": "107",
        "Proprietary Name": "ARIXTRA",
        "Dosage Form": "Injection",
        "Strength": "7.5 mg / 0.6 mL",
        "NDA Applicant Name": "Mylan Ireland Limited",
        "Date Authorized Generic Entered the Market": "12/2014 - 12/2015"
    },
    {
        "id": "108",
        "Proprietary Name": "ARIXTRA",
        "Dosage Form": "Injection",
        "Strength": "5 mg / 0.4 mL",
        "NDA Applicant Name": "Mylan Ireland Limited",
        "Date Authorized Generic Entered the Market": "12/2014 - 12/2015"
    },
    {
        "id": "109",
        "Proprietary Name": "ARIXTRA",
        "Dosage Form": "Injection",
        "Strength": "2.5 mg / 0.5 mL",
        "NDA Applicant Name": "Mylan Ireland Limited",
        "Date Authorized Generic Entered the Market": "12/2014 - 12/2015"
    },
    {
        "id": "110",
        "Proprietary Name": "ARIXTRA",
        "Dosage Form": "Injection",
        "Strength": "10 mg / 0.8 mL",
        "NDA Applicant Name": "Mylan Ireland Limited",
        "Date Authorized Generic Entered the Market": "12/2014 - 12/2015"
    },
    {
        "id": "111",
        "Proprietary Name": "AROMASIN",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "11/02/2010"
    },
    {
        "id": "112",
        "Proprietary Name": "ARTHROTEC",
        "Dosage Form": "Tablets",
        "Strength": "75 mg/200 mcg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "07/10/2011"
    },
    {
        "id": "113",
        "Proprietary Name": "ARTHROTEC",
        "Dosage Form": "Tablets",
        "Strength": "50 mg/200 mcg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "07/10/2011"
    },
    {
        "id": "114",
        "Proprietary Name": "ATACAND",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/21/2013"
    },
    {
        "id": "115",
        "Proprietary Name": "ATACAND",
        "Dosage Form": "Tablets",
        "Strength": "16 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/21/2013"
    },
    {
        "id": "116",
        "Proprietary Name": "ATACAND",
        "Dosage Form": "Tablets",
        "Strength": "32 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/21/2013"
    },
    {
        "id": "117",
        "Proprietary Name": "ATACAND",
        "Dosage Form": "Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/21/2013"
    },
    {
        "id": "118",
        "Proprietary Name": "ATACAND HCT",
        "Dosage Form": "Tablets",
        "Strength": "32 mg/25 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "09/2018"
    },
    {
        "id": "119",
        "Proprietary Name": "ATACAND HCT",
        "Dosage Form": "Tablets",
        "Strength": "16 mg/12.5 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "09/2018"
    },
    {
        "id": "120",
        "Proprietary Name": "ATACAND HCT",
        "Dosage Form": "Tablets",
        "Strength": "32 mg/12.5 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "09/2018"
    },
    {
        "id": "121",
        "Proprietary Name": "ATELVIA",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "35 mg",
        "NDA Applicant Name": "Allergan",
        "Date Authorized Generic Entered the Market": "2015"
    },
    {
        "id": "122",
        "Proprietary Name": "ATIVAN",
        "Dosage Form": "Injection",
        "Strength": "2 mg/mL",
        "NDA Applicant Name": "Baxter Healthcare Corporation",
        "Date Authorized Generic Entered the Market": "10/31/2003"
    },
    {
        "id": "123",
        "Proprietary Name": "ATIVAN",
        "Dosage Form": "Injection",
        "Strength": "4 mg/mL",
        "NDA Applicant Name": "Baxter Healthcare Corporation",
        "Date Authorized Generic Entered the Market": "10/31/2003"
    },
    {
        "id": "124",
        "Proprietary Name": "ATRALIN",
        "Dosage Form": "Gel",
        "Strength": "0.05%",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "07/26/2007"
    },
    {
        "id": "125",
        "Proprietary Name": "ATROPINE SULFATE OPHTHALMIC SOLUTION",
        "Dosage Form": "Sterile Ophthalmic Solution",
        "Strength": "1%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "4/23/2023"
    },
    {
        "id": "126",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Oral Suspension",
        "Strength": "200 mg/28.5 mg per 5 mL",
        "NDA Applicant Name": "Dr. Reddy's Laboratories Inc.",
        "Date Authorized Generic Entered the Market": "10/22/1990"
    },
    {
        "id": "127",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Oral Suspension",
        "Strength": "400 mg/57 mg per 5 mL",
        "NDA Applicant Name": "Dr. Reddy's Laboratories Inc.",
        "Date Authorized Generic Entered the Market": "10/22/1990"
    },
    {
        "id": "128",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "250mg/62.5mg/5mL",
        "NDA Applicant Name": "USAntibiotics, LLC",
        "Date Authorized Generic Entered the Market": "12/5/2022"
    },
    {
        "id": "129",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Dr. Reddy's Laboratories Inc.",
        "Date Authorized Generic Entered the Market": "10/22/1990"
    },
    {
        "id": "130",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Dr. Reddy's Laboratories Inc.",
        "Date Authorized Generic Entered the Market": "10/22/1990"
    },
    {
        "id": "131",
        "Proprietary Name": "AUGMENTIN",
        "Dosage Form": "Tablets",
        "Strength": "875 mg",
        "NDA Applicant Name": "Dr. Reddy's Laboratories Inc.",
        "Date Authorized Generic Entered the Market": "10/02/1996"
    },
    {
        "id": "132",
        "Proprietary Name": "AVALIDE",
        "Dosage Form": "Tablets",
        "Strength": "150 mg/12.5 mg",
        "NDA Applicant Name": "Sanofi-Aventis LLC",
        "Date Authorized Generic Entered the Market": "09/01/2011 - 08/31/2012, 09/2019"
    },
    {
        "id": "133",
        "Proprietary Name": "AVALIDE",
        "Dosage Form": "Tablets",
        "Strength": "300 mg/12.5 mg",
        "NDA Applicant Name": "Sanofi-Aventis LLC",
        "Date Authorized Generic Entered the Market": "09/01/2011 - 08/31/2012, 09/2019"
    },
    {
        "id": "134",
        "Proprietary Name": "AVAPRO",
        "Dosage Form": "Tablets",
        "Strength": "75 mg",
        "NDA Applicant Name": "Sanofi-Aventis LLC",
        "Date Authorized Generic Entered the Market": "09/01/2011 - 08/31/2012, 09/2019"
    },
    {
        "id": "135",
        "Proprietary Name": "AVAPRO",
        "Dosage Form": "Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "Sanofi-Aventis LLC",
        "Date Authorized Generic Entered the Market": "09/01/2011 - 08/31/2012, 09/2019"
    },
    {
        "id": "136",
        "Proprietary Name": "AVAPRO",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Sanofi-Aventis LLC",
        "Date Authorized Generic Entered the Market": "09/01/2011 - 08/31/2012, 09/2019"
    },
    {
        "id": "137",
        "Proprietary Name": "AVELOX",
        "Dosage Form": "Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "Bayer HealthCare LLC",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "138",
        "Proprietary Name": "AVITA",
        "Dosage Form": "Cream",
        "Strength": "0.025%",
        "NDA Applicant Name": "Mylan Pharmaceuticals, Inc., a Viatris Company",
        "Date Authorized Generic Entered the Market": "05/01/1998"
    },
    {
        "id": "139",
        "Proprietary Name": "AZILECT",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "140",
        "Proprietary Name": "AZILECT",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "141",
        "Proprietary Name": "AZOPT",
        "Dosage Form": "Ophthalmic Suspension",
        "Strength": "1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "03/2021"
    },
    {
        "id": "142",
        "Proprietary Name": "AZULFIDINE",
        "Dosage Form": "Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "07/14/2003"
    },
    {
        "id": "143",
        "Proprietary Name": "AZULFIDINE EN- TABS",
        "Dosage Form": "Delayed Release Tablets",
        "Strength": "500mg ECT",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "3/2022"
    },
    {
        "id": "144",
        "Proprietary Name": "BENICAR HCT",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/25 mg",
        "NDA Applicant Name": "Daiichi Sankyo, Inc",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "145",
        "Proprietary Name": "BENICAR HCT",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/12.5 mg",
        "NDA Applicant Name": "Daiichi Sankyo, Inc",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "146",
        "Proprietary Name": "BENICAR HCT",
        "Dosage Form": "Tablets",
        "Strength": "20 mg/12.5 mg",
        "NDA Applicant Name": "Daiichi Sankyo, Inc",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "147",
        "Proprietary Name": "BENZACLIN",
        "Dosage Form": "Topical Gel",
        "Strength": "1% / 5%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "148",
        "Proprietary Name": "BENZAMYCIN",
        "Dosage Form": "Topical Gel",
        "Strength": "3% Erythromycin, 5% Benzoyl Peroxide",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "10/2014 - 10/2015"
    },
    {
        "id": "149",
        "Proprietary Name": "BEPREVE",
        "Dosage Form": "Solution",
        "Strength": "1.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "05/2021"
    },
    {
        "id": "150",
        "Proprietary Name": "BETHKIS",
        "Dosage Form": "Inhalation Solution",
        "Strength": "300 mg/4 mL",
        "NDA Applicant Name": "Chiesi USA, Inc.",
        "Date Authorized Generic Entered the Market": "09/2020"
    },
    {
        "id": "151",
        "Proprietary Name": "BETOPTIC",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "eq. 0.5% base",
        "NDA Applicant Name": "Alcon Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "05/08/2000"
    },
    {
        "id": "152",
        "Proprietary Name": "BICNU",
        "Dosage Form": "Lyophilized Powder for Injection",
        "Strength": "100 mg/vial",
        "NDA Applicant Name": "Avet Lifesciences Private Limited",
        "Date Authorized Generic Entered the Market": "03/01/2021"
    },
    {
        "id": "153",
        "Proprietary Name": "BiCNU",
        "Dosage Form": "Powder for Injection",
        "Strength": "100 mg/vial",
        "NDA Applicant Name": "Avet Lifesciences Private Ltd.",
        "Date Authorized Generic Entered the Market": "10/2019"
    },
    {
        "id": "154",
        "Proprietary Name": "BIDIL",
        "Dosage Form": "Tablets",
        "Strength": "20 mg/37.5 mg",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "04/2022"
    },
    {
        "id": "155",
        "Proprietary Name": "BLOCADREN",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Merck & Co., Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "156",
        "Proprietary Name": "BLOCADREN",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Merck & Co., Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "157",
        "Proprietary Name": "BREO ELLIPTA",
        "Dosage Form": "Inhalation Powder",
        "Strength": "100 ug/1, 25ug/1",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Development",
        "Date Authorized Generic Entered the Market": "5/23/2022"
    },
    {
        "id": "158",
        "Proprietary Name": "BREO ELLIPTA",
        "Dosage Form": "Inhalation Powder",
        "Strength": "200ug/1, 25 ug/1",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Development",
        "Date Authorized Generic Entered the Market": "05/23/2022"
    },
    {
        "id": "159",
        "Proprietary Name": "BREVIBLOC",
        "Dosage Form": "Injection",
        "Strength": "10 mg/mL",
        "NDA Applicant Name": "Baxter Healthcare Corporation",
        "Date Authorized Generic Entered the Market": "11/2002 - 10/2003"
    },
    {
        "id": "160",
        "Proprietary Name": "BRISDELLE",
        "Dosage Form": "Capsules",
        "Strength": "7.5 mg",
        "NDA Applicant Name": "Sebela Ireland Limited",
        "Date Authorized Generic Entered the Market": "10/2017"
    },
    {
        "id": "161",
        "Proprietary Name": "BUMEX",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "162",
        "Proprietary Name": "BUMEX",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "163",
        "Proprietary Name": "BUMEX",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "164",
        "Proprietary Name": "BUTRANS",
        "Dosage Form": "Transdermal System",
        "Strength": "7.5 mcg/hour",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "165",
        "Proprietary Name": "BUTRANS",
        "Dosage Form": "Transdermal System",
        "Strength": "20 mcg/hour",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "166",
        "Proprietary Name": "BUTRANS",
        "Dosage Form": "Transdermal System",
        "Strength": "15 mcg/hour",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "167",
        "Proprietary Name": "BUTRANS",
        "Dosage Form": "Transdermal System",
        "Strength": "5 mcg/hour",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "168",
        "Proprietary Name": "BUTRANS",
        "Dosage Form": "Transdermal System",
        "Strength": "10 mcg/hour",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "169",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "2.5/10 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "03/14/2022"
    },
    {
        "id": "170",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "10/20 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "171",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "10/10 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "172",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "2.5/20 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "173",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "5/80 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "174",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "5/40 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "175",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "10/40 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "176",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "10/80 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "177",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "5/10 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "178",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "5/20 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "179",
        "Proprietary Name": "CADUET",
        "Dosage Form": "Tablet",
        "Strength": "2.5/40 mg",
        "NDA Applicant Name": "Pharmacia & Upjohn Co. LLC",
        "Date Authorized Generic Entered the Market": "3/14/2022"
    },
    {
        "id": "180",
        "Proprietary Name": "CANASA",
        "Dosage Form": "Suppository",
        "Strength": "1000 mg",
        "NDA Applicant Name": "AbbVie, Inc.",
        "Date Authorized Generic Entered the Market": "12/2018"
    },
    {
        "id": "181",
        "Proprietary Name": "CARAFATE",
        "Dosage Form": "Oral Suspension",
        "Strength": "1 g/10 mL",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "12/2019"
    },
    {
        "id": "182",
        "Proprietary Name": "CARAFATE",
        "Dosage Form": "Tablets",
        "Strength": "1 g",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/01/1996"
    },
    {
        "id": "183",
        "Proprietary Name": "CARBATROL",
        "Dosage Form": "Extended- Release Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "184",
        "Proprietary Name": "CARBATROL",
        "Dosage Form": "Extended- Release Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "185",
        "Proprietary Name": "CARBATROL",
        "Dosage Form": "Extended- Release Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "186",
        "Proprietary Name": "CARDIOLITE",
        "Dosage Form": "Injection",
        "Strength": "(per label)",
        "NDA Applicant Name": "Lantheus Medical Imaging, Inc.",
        "Date Authorized Generic Entered the Market": "12/1990"
    },
    {
        "id": "187",
        "Proprietary Name": "CARDIZEM",
        "Dosage Form": "Tablets",
        "Strength": "30 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/25/2010"
    },
    {
        "id": "188",
        "Proprietary Name": "CARDIZEM",
        "Dosage Form": "Tablets",
        "Strength": "60 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/25/2010"
    },
    {
        "id": "189",
        "Proprietary Name": "CARDIZEM",
        "Dosage Form": "Tablets",
        "Strength": "90 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/25/2010"
    },
    {
        "id": "190",
        "Proprietary Name": "CARDIZEM",
        "Dosage Form": "Tablets",
        "Strength": "120 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/25/2010"
    },
    {
        "id": "191",
        "Proprietary Name": "CARDIZEM CD",
        "Dosage Form": "Capsules",
        "Strength": "360 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/09/2012"
    },
    {
        "id": "192",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Extended Release Tablets",
        "Strength": "120 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "2/6/2014"
    },
    {
        "id": "193",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Tablets",
        "Strength": "180 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "02/06/2014"
    },
    {
        "id": "194",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Tablets",
        "Strength": "420 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "02/06/2014"
    },
    {
        "id": "195",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Tablets",
        "Strength": "360 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "02/06/2014"
    },
    {
        "id": "196",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "02/06/2014"
    },
    {
        "id": "197",
        "Proprietary Name": "CARDIZEM LA",
        "Dosage Form": "Tablets",
        "Strength": "240 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "02/06/2014"
    },
    {
        "id": "198",
        "Proprietary Name": "CARDURA",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "07/2014, 10/2021"
    },
    {
        "id": "199",
        "Proprietary Name": "CARDURA",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "07/2014"
    },
    {
        "id": "200",
        "Proprietary Name": "CARDURA",
        "Dosage Form": "Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "07/2014, 10/2021"
    },
    {
        "id": "201",
        "Proprietary Name": "CARDURA",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "07/2014, 11/2021"
    },
    {
        "id": "202",
        "Proprietary Name": "CARNITOR",
        "Dosage Form": "Oral Solution",
        "Strength": "1 g/10 mL",
        "NDA Applicant Name": "Leadiant Biosciences, Inc.",
        "Date Authorized Generic Entered the Market": "04/2005 - 04/2006"
    },
    {
        "id": "203",
        "Proprietary Name": "CARNITOR",
        "Dosage Form": "Tablets",
        "Strength": "330 mg",
        "NDA Applicant Name": "Leadiant Biosciences, Inc.",
        "Date Authorized Generic Entered the Market": "1/2005 - 12/2005"
    },
    {
        "id": "204",
        "Proprietary Name": "CASODEX",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2020"
    },
    {
        "id": "205",
        "Proprietary Name": "CASPORYN HC",
        "Dosage Form": "Otic Suspension",
        "Strength": "3.5 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "03/15/2019"
    },
    {
        "id": "206",
        "Proprietary Name": "CEDAX",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Pernix Therapeutics LLC",
        "Date Authorized Generic Entered the Market": "10/22/2013"
    },
    {
        "id": "207",
        "Proprietary Name": "CEDAX",
        "Dosage Form": "Powder, for Oral Suspension",
        "Strength": "60 mL when reconstituted (180 mg per 5 mL)",
        "NDA Applicant Name": "Pernix Therapeutics LLC",
        "Date Authorized Generic Entered the Market": "10/22/2013"
    },
    {
        "id": "208",
        "Proprietary Name": "CELEBREX",
        "Dosage Form": "Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "12/10/2014"
    },
    {
        "id": "209",
        "Proprietary Name": "CELEBREX",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "12/10/2014"
    },
    {
        "id": "210",
        "Proprietary Name": "CELEBREX",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "12/10/2014"
    },
    {
        "id": "211",
        "Proprietary Name": "CELEBREX",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "12/10/2014"
    },
    {
        "id": "212",
        "Proprietary Name": "CETRAXAL",
        "Dosage Form": "Otic Solution",
        "Strength": "0.2%",
        "NDA Applicant Name": "Wraser Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "08/2012"
    },
    {
        "id": "213",
        "Proprietary Name": "CHILDREN'S MOTRIN",
        "Dosage Form": "Suspension",
        "Strength": "100 mg/5 mL",
        "NDA Applicant Name": "McNeil Consumer Healthcare",
        "Date Authorized Generic Entered the Market": "06/1998 - 06/1999"
    },
    {
        "id": "214",
        "Proprietary Name": "CHILDREN'S MOTRIN (aka INFANT'S MOTRIN)",
        "Dosage Form": "Suspension/ Drops",
        "Strength": "40 mg/mL",
        "NDA Applicant Name": "McNeil Consumer Healthcare",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "215",
        "Proprietary Name": "CILOXAN",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.3%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "05/28/2004"
    },
    {
        "id": "216",
        "Proprietary Name": "CIPRO",
        "Dosage Form": "for Oral Suspension",
        "Strength": "250 mg/5 mL",
        "NDA Applicant Name": "Bayer Pharmaceuticals Corp.",
        "Date Authorized Generic Entered the Market": "06/2003"
    },
    {
        "id": "217",
        "Proprietary Name": "CIPRO",
        "Dosage Form": "for Oral Suspension",
        "Strength": "500 mg/5 mL",
        "NDA Applicant Name": "Bayer Pharmaceuticals Corp.",
        "Date Authorized Generic Entered the Market": "06/2003"
    },
    {
        "id": "218",
        "Proprietary Name": "CIPRODEX",
        "Dosage Form": "Otic Suspension",
        "Strength": "0.3% & 0.1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "219",
        "Proprietary Name": "CLEOCIN",
        "Dosage Form": "Vaginal Cream",
        "Strength": "2%",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "12/17/2005"
    },
    {
        "id": "220",
        "Proprietary Name": "CLEOCIN HCl",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "07/11/2003"
    },
    {
        "id": "221",
        "Proprietary Name": "CLEOCIN HCl",
        "Dosage Form": "Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "222",
        "Proprietary Name": "CLEOCIN PHOSPHATE",
        "Dosage Form": "Injection",
        "Strength": "300 mg/2 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "223",
        "Proprietary Name": "CLEOCIN PHOSPHATE",
        "Dosage Form": "Injection",
        "Strength": "9,000/60 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "224",
        "Proprietary Name": "CLEOCIN PHOSPHATE",
        "Dosage Form": "Injection",
        "Strength": "900 mg/6 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "225",
        "Proprietary Name": "CLEOCIN PHOSPHATE",
        "Dosage Form": "Injection",
        "Strength": "600 mg/4 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "226",
        "Proprietary Name": "CLEOCIN T",
        "Dosage Form": "Topical Gel",
        "Strength": "1%",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/11/2003"
    },
    {
        "id": "227",
        "Proprietary Name": "CLEOCIN T",
        "Dosage Form": "Topical Lotion",
        "Strength": "1%",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "228",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "0.375 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "229",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "0.05 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "230",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "0.06 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "231",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "0.075 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "232",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "1 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "233",
        "Proprietary Name": "CLIMARA",
        "Dosage Form": "Transdermal System",
        "Strength": "0.025 mg/day",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "234",
        "Proprietary Name": "CLINDAGEL",
        "Dosage Form": "Gel",
        "Strength": "1%",
        "NDA Applicant Name": "Bausch Health U.S., LLC",
        "Date Authorized Generic Entered the Market": "06/2018"
    },
    {
        "id": "235",
        "Proprietary Name": "CLINORIL",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Merck & Co., Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "236",
        "Proprietary Name": "CLINORIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Merck & Co., Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "237",
        "Proprietary Name": "CLOBEX",
        "Dosage Form": "Shampoo",
        "Strength": "0.05%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "1/2024"
    },
    {
        "id": "238",
        "Proprietary Name": "CLOBEX",
        "Dosage Form": "Spray",
        "Strength": "0.05%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "08/2015"
    },
    {
        "id": "239",
        "Proprietary Name": "CLODERM",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "EPI Health, LLC",
        "Date Authorized Generic Entered the Market": "09/2019"
    },
    {
        "id": "240",
        "Proprietary Name": "CLODERM",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "EPI Health, LLC",
        "Date Authorized Generic Entered the Market": "02/17/2014"
    },
    {
        "id": "241",
        "Proprietary Name": "CLOLAR",
        "Dosage Form": "Injection",
        "Strength": "20mg/20mL",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "242",
        "Proprietary Name": "CLOMID",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Hoechst Marion Roussel, Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "243",
        "Proprietary Name": "CLOZARIL",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Heritage Life Sciences (USA), Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "244",
        "Proprietary Name": "CLOZARIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Heritage Life Sciences (USA), Inc.",
        "Date Authorized Generic Entered the Market": "05/2020"
    },
    {
        "id": "245",
        "Proprietary Name": "CLOZARIL",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Heritage Life Sciences (USA), Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "246",
        "Proprietary Name": "CLOZARIL",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Heritage Life Sciences (USA), Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "247",
        "Proprietary Name": "COLCRYS",
        "Dosage Form": "Tablets",
        "Strength": "0.6 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A. Inc.",
        "Date Authorized Generic Entered the Market": "07/01/2018"
    },
    {
        "id": "248",
        "Proprietary Name": "COLESTID",
        "Dosage Form": "Granules for Oral Suspension",
        "Strength": "5 g per dose",
        "NDA Applicant Name": "Pharmacia and Upjohn LLC",
        "Date Authorized Generic Entered the Market": "01/11/2016"
    },
    {
        "id": "249",
        "Proprietary Name": "COLESTID",
        "Dosage Form": "Tablets",
        "Strength": "1 g",
        "NDA Applicant Name": "Pharmacia and Upjohn LLC",
        "Date Authorized Generic Entered the Market": "02/2007"
    },
    {
        "id": "250",
        "Proprietary Name": "COLY-MYCIN M",
        "Dosage Form": "for Injection",
        "Strength": "150 mg/vial (single dose vial)",
        "NDA Applicant Name": "Par Sterile Products, LLC",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "251",
        "Proprietary Name": "COMTAN",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/04/2014"
    },
    {
        "id": "252",
        "Proprietary Name": "CONCERTA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "18 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "253",
        "Proprietary Name": "CONCERTA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "27 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "254",
        "Proprietary Name": "CONCERTA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "36 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "255",
        "Proprietary Name": "CONCERTA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "54 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "256",
        "Proprietary Name": "CONDYLOX",
        "Dosage Form": "Topical Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Teva Branded Pharmaceuticals Products R&D, Inc",
        "Date Authorized Generic Entered the Market": "12/16/2003"
    },
    {
        "id": "257",
        "Proprietary Name": "CONZIP",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Cipher Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2015"
    },
    {
        "id": "258",
        "Proprietary Name": "CONZIP",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Cipher Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "259",
        "Proprietary Name": "CONZIP",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Cipher Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2015"
    },
    {
        "id": "260",
        "Proprietary Name": "COREG CR",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "SmithKline Beecham (Cork) Ltd, Ireland",
        "Date Authorized Generic Entered the Market": "11/2017"
    },
    {
        "id": "261",
        "Proprietary Name": "COREG CR",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "SmithKline Beecham (Cork) Ltd, Ireland",
        "Date Authorized Generic Entered the Market": "11/2017"
    },
    {
        "id": "262",
        "Proprietary Name": "COREG CR",
        "Dosage Form": "Capsules",
        "Strength": "80 mg",
        "NDA Applicant Name": "SmithKline Beecham (Cork) Ltd, Ireland",
        "Date Authorized Generic Entered the Market": "11/2017"
    },
    {
        "id": "263",
        "Proprietary Name": "COREG CR",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "SmithKline Beecham (Cork) Ltd, Ireland",
        "Date Authorized Generic Entered the Market": "11/2017"
    },
    {
        "id": "264",
        "Proprietary Name": "CORGARD",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "US WorldMeds, LLC",
        "Date Authorized Generic Entered the Market": "05/05/2014"
    },
    {
        "id": "265",
        "Proprietary Name": "CORGARD",
        "Dosage Form": "Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "US WorldMeds, LLC",
        "Date Authorized Generic Entered the Market": "05/05/2014"
    },
    {
        "id": "266",
        "Proprietary Name": "CORGARD",
        "Dosage Form": "Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "US WorldMeds, LLC",
        "Date Authorized Generic Entered the Market": "05/05/2014"
    },
    {
        "id": "267",
        "Proprietary Name": "CORTEF",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn Company LLC",
        "Date Authorized Generic Entered the Market": "12/21/2012"
    },
    {
        "id": "268",
        "Proprietary Name": "CORTEF",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn Company LLC",
        "Date Authorized Generic Entered the Market": "12/21/2012"
    },
    {
        "id": "269",
        "Proprietary Name": "CORTEF",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn Company LLC",
        "Date Authorized Generic Entered the Market": "12/22/2012"
    },
    {
        "id": "270",
        "Proprietary Name": "CORTENEMA",
        "Dosage Form": "Rectal Suspension",
        "Strength": "100 mg/60 mL",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2012"
    },
    {
        "id": "271",
        "Proprietary Name": "CORTISPORIN OTIC",
        "Dosage Form": "Otic Solution",
        "Strength": "eq. 3.5 mg base/g; 10,000 units/g; 1%",
        "NDA Applicant Name": "Monarch Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "1/11/1999"
    },
    {
        "id": "272",
        "Proprietary Name": "COSMEGEN",
        "Dosage Form": "Powder, for injection solution, lyophilized",
        "Strength": "500 mcg (0.5 mg)",
        "NDA Applicant Name": "Recordati Rare Diseases Inc.",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "273",
        "Proprietary Name": "CUPRIMINE",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "12/1970"
    },
    {
        "id": "274",
        "Proprietary Name": "CUTIVATE",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "GlaxoSmithKline Consumer Healthcare",
        "Date Authorized Generic Entered the Market": "11/2003 - 11/2004"
    },
    {
        "id": "275",
        "Proprietary Name": "CUTIVATE",
        "Dosage Form": "Ointment",
        "Strength": "0.005%",
        "NDA Applicant Name": "GlaxoSmithKline Consumer Healthcare",
        "Date Authorized Generic Entered the Market": "11/2003 - 11/2004"
    },
    {
        "id": "276",
        "Proprietary Name": "CYCLESSA",
        "Dosage Form": "Tablets",
        "Strength": "0.1 mg, 0.125 mg, 0.15 mg; 0.025 mg, 0.025 mg, 0.025 mg",
        "NDA Applicant Name": "Organon USA Inc.",
        "Date Authorized Generic Entered the Market": "9/15/2004"
    },
    {
        "id": "277",
        "Proprietary Name": "CYTOMEL",
        "Dosage Form": "Tablets",
        "Strength": "5 mcg",
        "NDA Applicant Name": "King Pharmaceuticals R&D LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "278",
        "Proprietary Name": "CYTOMEL",
        "Dosage Form": "Tablets",
        "Strength": "50 mcg",
        "NDA Applicant Name": "King Pharmaceuticals R&D LLC",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "279",
        "Proprietary Name": "CYTOMEL",
        "Dosage Form": "Tablets",
        "Strength": "25 mcg",
        "NDA Applicant Name": "King Pharmaceuticals R&D LLC",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "280",
        "Proprietary Name": "CYTOTEC",
        "Dosage Form": "Tablets",
        "Strength": "100 mcg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "281",
        "Proprietary Name": "CYTOTEC",
        "Dosage Form": "Tablets",
        "Strength": "200 mcg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "282",
        "Proprietary Name": "DANTRIUM",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Par Sterile Products, LLC",
        "Date Authorized Generic Entered the Market": "02/2016"
    },
    {
        "id": "283",
        "Proprietary Name": "DANTRIUM",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Par Sterile Products, LLC",
        "Date Authorized Generic Entered the Market": "04/08/2013"
    },
    {
        "id": "284",
        "Proprietary Name": "DANTRIUM",
        "Dosage Form": "Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Par Sterile Products, LLC",
        "Date Authorized Generic Entered the Market": "04/08/2013"
    },
    {
        "id": "285",
        "Proprietary Name": "DARAPRIM",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Vyera Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "286",
        "Proprietary Name": "DAYPRO",
        "Dosage Form": "Caplets",
        "Strength": "600 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/28/2013"
    },
    {
        "id": "287",
        "Proprietary Name": "DAYTRANA",
        "Dosage Form": "Patches",
        "Strength": "82.5 mg",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/05/2023"
    },
    {
        "id": "288",
        "Proprietary Name": "DAYTRANA",
        "Dosage Form": "Patches",
        "Strength": "55.0 mg",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/05/2023"
    },
    {
        "id": "289",
        "Proprietary Name": "DAYTRANA",
        "Dosage Form": "Patches",
        "Strength": "41.3 mg",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/05/2023"
    },
    {
        "id": "290",
        "Proprietary Name": "DAYTRANA",
        "Dosage Form": "Patches",
        "Strength": "27.5 mg",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/05/2023"
    },
    {
        "id": "291",
        "Proprietary Name": "DDAVP",
        "Dosage Form": "Nasal Solution",
        "Strength": "10 mcg / 0.1 mL",
        "NDA Applicant Name": "Ferring Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "07/2016"
    },
    {
        "id": "292",
        "Proprietary Name": "DDAVP",
        "Dosage Form": "Tablets",
        "Strength": "0.1 mg",
        "NDA Applicant Name": "Ferring Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2015"
    },
    {
        "id": "293",
        "Proprietary Name": "DDAVP",
        "Dosage Form": "Tablets",
        "Strength": "0.2 mg",
        "NDA Applicant Name": "Ferring Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2015"
    },
    {
        "id": "294",
        "Proprietary Name": "DDAVP, DESMOPRESSIN ACETATE",
        "Dosage Form": "Injection",
        "Strength": "4 mcg/mL",
        "NDA Applicant Name": "Ferring Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "01/2016"
    },
    {
        "id": "295",
        "Proprietary Name": "DELESTROGEN",
        "Dosage Form": "Injection",
        "Strength": "20 mg/mL",
        "NDA Applicant Name": "Par Sterile Products",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "296",
        "Proprietary Name": "DELESTROGEN",
        "Dosage Form": "Injection",
        "Strength": "10 mg/mL",
        "NDA Applicant Name": "Par Sterile Products",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "297",
        "Proprietary Name": "DELESTROGEN",
        "Dosage Form": "Injection",
        "Strength": "40 mg/mL",
        "NDA Applicant Name": "Par Sterile Products",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "298",
        "Proprietary Name": "DEMSER",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "09/07/2020"
    },
    {
        "id": "299",
        "Proprietary Name": "DENAVIR",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "11/16/2022"
    },
    {
        "id": "300",
        "Proprietary Name": "DEPAKOTE ER",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Abbvie Inc.",
        "Date Authorized Generic Entered the Market": "08/2013"
    },
    {
        "id": "301",
        "Proprietary Name": "DEPAKOTE ER",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Abbvie Inc.",
        "Date Authorized Generic Entered the Market": "08/2013"
    },
    {
        "id": "302",
        "Proprietary Name": "DEPAKOTE SPRINKLE CAPSULES",
        "Dosage Form": "Capsules",
        "Strength": "125 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "08/31/2015"
    },
    {
        "id": "303",
        "Proprietary Name": "DEPO-MEDROL",
        "Dosage Form": "Injection",
        "Strength": "40 mg/mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "05/2006 - 05/2007"
    },
    {
        "id": "304",
        "Proprietary Name": "DEPO-MEDROL",
        "Dosage Form": "Injection",
        "Strength": "80 mg/mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "05/2006 - 05/2007"
    },
    {
        "id": "305",
        "Proprietary Name": "DEPO-PROVERA",
        "Dosage Form": "Injection",
        "Strength": "150 mg in 1 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "7/13/2021"
    },
    {
        "id": "306",
        "Proprietary Name": "DEPO-PROVERA",
        "Dosage Form": "Injection",
        "Strength": "150 mg in 1 mL",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "09/16/2004"
    },
    {
        "id": "307",
        "Proprietary Name": "DERMA- SMOOTHE/FS (Body Oil)",
        "Dosage Form": "Oil",
        "Strength": "0.01%",
        "NDA Applicant Name": "Hill Dermaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/2013"
    },
    {
        "id": "308",
        "Proprietary Name": "DERMA- SMOOTHE/FS (Scalp Oil)",
        "Dosage Form": "Oil",
        "Strength": "0.01%",
        "NDA Applicant Name": "Hill Dermaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/2013"
    },
    {
        "id": "309",
        "Proprietary Name": "DERMOTIC",
        "Dosage Form": "Oil",
        "Strength": "0.01%",
        "NDA Applicant Name": "Hill Dermaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/2013"
    },
    {
        "id": "310",
        "Proprietary Name": "DERMOTIC OIL",
        "Dosage Form": "Oil",
        "Strength": "0.01%",
        "NDA Applicant Name": "Hill Dermaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/20/2013"
    },
    {
        "id": "311",
        "Proprietary Name": "DESMOPRESSIN ACETATE",
        "Dosage Form": "Nasal Spray",
        "Strength": "10 mcg per 0.1 mL (5 mL bottle)",
        "NDA Applicant Name": "Ferring Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "11/20/2014"
    },
    {
        "id": "312",
        "Proprietary Name": "DESOWEN",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "07/2013"
    },
    {
        "id": "313",
        "Proprietary Name": "DETROL",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "01/2014, 01/2016"
    },
    {
        "id": "314",
        "Proprietary Name": "DETROL",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "315",
        "Proprietary Name": "DETROL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "4 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "316",
        "Proprietary Name": "DETROL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "2 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "01/2016"
    },
    {
        "id": "317",
        "Proprietary Name": "DEXEDRINE SPANSULE",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Impax Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "08/1976"
    },
    {
        "id": "318",
        "Proprietary Name": "DEXEDRINE SPANSULE",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Impax Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "08/1976"
    },
    {
        "id": "319",
        "Proprietary Name": "DEXEDRINE SPANSULE",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Impax Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "08/1976"
    },
    {
        "id": "320",
        "Proprietary Name": "DEXILANT",
        "Dosage Form": "Delayed-release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "01/2022"
    },
    {
        "id": "321",
        "Proprietary Name": "DEXILANT",
        "Dosage Form": "Delayed-release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "01/2022"
    },
    {
        "id": "322",
        "Proprietary Name": "DIABETA",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Sanofi-Aventis U.S., LLC",
        "Date Authorized Generic Entered the Market": "05/01/1984"
    },
    {
        "id": "323",
        "Proprietary Name": "DIABETA",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Sanofi-Aventis U.S., LLC",
        "Date Authorized Generic Entered the Market": "05/01/1984"
    },
    {
        "id": "324",
        "Proprietary Name": "DIAMOX SEQUELS",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "500 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "12/2008"
    },
    {
        "id": "325",
        "Proprietary Name": "DIASTAT ACUDIAL",
        "Dosage Form": "Gel",
        "Strength": "20 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/1997"
    },
    {
        "id": "326",
        "Proprietary Name": "DIASTAT ACUDIAL",
        "Dosage Form": "Gel",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/1997"
    },
    {
        "id": "327",
        "Proprietary Name": "DIASTAT ACUDIAL",
        "Dosage Form": "Gel",
        "Strength": "10 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/1997"
    },
    {
        "id": "328",
        "Proprietary Name": "DIBENZYLINE",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/11/2015"
    },
    {
        "id": "329",
        "Proprietary Name": "DICLEGIS",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "10 mg/10 mg",
        "NDA Applicant Name": "Duchesnay Inc.",
        "Date Authorized Generic Entered the Market": "11/2018"
    },
    {
        "id": "330",
        "Proprietary Name": "DIFFERIN CREAM 0.1%",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "10/2010"
    },
    {
        "id": "331",
        "Proprietary Name": "DIFFERIN GEL",
        "Dosage Form": "Gel",
        "Strength": "0.3%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "04/2024"
    },
    {
        "id": "332",
        "Proprietary Name": "DIFFERIN GEL 0.1%",
        "Dosage Form": "Gel",
        "Strength": "0.1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "08/23/2010"
    },
    {
        "id": "333",
        "Proprietary Name": "DIFLUCAN",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "10 mg/mL when reconstituted",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/12/2004"
    },
    {
        "id": "334",
        "Proprietary Name": "DIFLUCAN",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "40 mg/mL when reconstituted",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/12/2004"
    },
    {
        "id": "335",
        "Proprietary Name": "DIFLUCAN",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/12/2004"
    },
    {
        "id": "336",
        "Proprietary Name": "DIFLUCAN",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/12/2004"
    },
    {
        "id": "337",
        "Proprietary Name": "DIFLUCAN",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/12/2004"
    },
    {
        "id": "338",
        "Proprietary Name": "DILANTIN",
        "Dosage Form": "Tablet (INFATABS)",
        "Strength": "50 mg",
        "NDA Applicant Name": "Parke-Davis Division of Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "12/27/2012"
    },
    {
        "id": "339",
        "Proprietary Name": "DILANTIN-125",
        "Dosage Form": "Oral Suspension",
        "Strength": "125 mg/5 mL (237 mL bottle)",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "340",
        "Proprietary Name": "DILAUDID",
        "Dosage Form": "Solution",
        "Strength": "5 mg/5 mL (1 mg/mL)",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "10/1/2012"
    },
    {
        "id": "341",
        "Proprietary Name": "DILAUDID",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "11/23/2009"
    },
    {
        "id": "342",
        "Proprietary Name": "DILAUDID",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "11/23/2009"
    },
    {
        "id": "343",
        "Proprietary Name": "DILAUDID",
        "Dosage Form": "Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "Rhodes Pharmaceuticals L.P.",
        "Date Authorized Generic Entered the Market": "11/23/2009"
    },
    {
        "id": "344",
        "Proprietary Name": "DIPROLENE",
        "Dosage Form": "Ointment",
        "Strength": "0.05%",
        "NDA Applicant Name": "Organon LLC",
        "Date Authorized Generic Entered the Market": "8/10/2012"
    },
    {
        "id": "345",
        "Proprietary Name": "DITROPAN XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Janssen Research and Development, LLC",
        "Date Authorized Generic Entered the Market": "11/12/2015"
    },
    {
        "id": "346",
        "Proprietary Name": "DITROPAN XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Janssen Research and Development, LLC",
        "Date Authorized Generic Entered the Market": "11/12/2015"
    },
    {
        "id": "347",
        "Proprietary Name": "DIURIL",
        "Dosage Form": "Injection",
        "Strength": "500 mg/vial, sterile lyophilized",
        "NDA Applicant Name": "Oak Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/13/2012"
    },
    {
        "id": "348",
        "Proprietary Name": "DORAL",
        "Dosage Form": "Tablets",
        "Strength": "15 mg",
        "NDA Applicant Name": "Galt Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "8/8/13"
    },
    {
        "id": "349",
        "Proprietary Name": "DORIBAX",
        "Dosage Form": "Powder for Injection",
        "Strength": "500 mg/vial",
        "NDA Applicant Name": "Shionogi Inc.",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "350",
        "Proprietary Name": "DORIBAX",
        "Dosage Form": "Powder for Injection",
        "Strength": "250 mg/vial",
        "NDA Applicant Name": "Shionogi Inc.",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "351",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "07/08/2013"
    },
    {
        "id": "352",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "02/2016"
    },
    {
        "id": "353",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "05/2016"
    },
    {
        "id": "354",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "75 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "07/08/2013"
    },
    {
        "id": "355",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "07/08/2013"
    },
    {
        "id": "356",
        "Proprietary Name": "DORYX",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Mayne Pharma International Pty Ltd.",
        "Date Authorized Generic Entered the Market": "07/08/2013"
    },
    {
        "id": "357",
        "Proprietary Name": "DOSTINEX",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "09/22/2014"
    },
    {
        "id": "358",
        "Proprietary Name": "DOVONEX",
        "Dosage Form": "Cream",
        "Strength": "0.005%",
        "NDA Applicant Name": "LEO Pharma Inc.",
        "Date Authorized Generic Entered the Market": "2012"
    },
    {
        "id": "359",
        "Proprietary Name": "DOVONEX",
        "Dosage Form": "Ointment",
        "Strength": "0.005%",
        "NDA Applicant Name": "LEO Pharma Inc.",
        "Date Authorized Generic Entered the Market": "07/01/2013"
    },
    {
        "id": "360",
        "Proprietary Name": "DOXIL",
        "Dosage Form": "Injection (Liposomal formulation)",
        "Strength": "50 mg/25 mL single use vial",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "361",
        "Proprietary Name": "DOXIL",
        "Dosage Form": "Injection (Liposomal formulation)",
        "Strength": "20 mg/10 mL single use vial",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "07/2017"
    },
    {
        "id": "362",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "50 mg/25 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "4/1/2013"
    },
    {
        "id": "363",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "20 mg/10mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "03/17/2014"
    },
    {
        "id": "364",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "50 mg/25 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "03/17/2014"
    },
    {
        "id": "365",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "150 mg/75 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "4/1/2013"
    },
    {
        "id": "366",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "200 mg/ 100 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "03/17/2014"
    },
    {
        "id": "367",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "10 mg/5 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "03/17/2014"
    },
    {
        "id": "368",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "20 mg/10 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "4/1/2013"
    },
    {
        "id": "369",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "10 mg/5 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "4/1/2013"
    },
    {
        "id": "370",
        "Proprietary Name": "DOXORUBICIN",
        "Dosage Form": "Injection",
        "Strength": "200 mg/100 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "4/1/2013"
    },
    {
        "id": "371",
        "Proprietary Name": "DUETACT",
        "Dosage Form": "Tablets",
        "Strength": "30 mg / 2 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "08/04/2015"
    },
    {
        "id": "372",
        "Proprietary Name": "DUETACT",
        "Dosage Form": "Tablets",
        "Strength": "30 mg / 4 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "08/04/2015"
    },
    {
        "id": "373",
        "Proprietary Name": "DUEXIS",
        "Dosage Form": "Tablets",
        "Strength": "800 mg and 26.6 mg",
        "NDA Applicant Name": "Horizon Medicines LLC",
        "Date Authorized Generic Entered the Market": "09/2021"
    },
    {
        "id": "374",
        "Proprietary Name": "DUREZOL",
        "Dosage Form": "Ophthalmic Emulsion",
        "Strength": "0.05%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "09/2021"
    },
    {
        "id": "375",
        "Proprietary Name": "DYMISTA",
        "Dosage Form": "Nasal Spray",
        "Strength": "137 mcg/50 mcg per spray",
        "NDA Applicant Name": "Mylan Specialty, L.P.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "376",
        "Proprietary Name": "DYRENIUM",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "377",
        "Proprietary Name": "DYRENIUM",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "378",
        "Proprietary Name": "E.E.S. GRANULES",
        "Dosage Form": "Suspension",
        "Strength": "200 mg per 5 mL when reconstituted",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "09/2016"
    },
    {
        "id": "379",
        "Proprietary Name": "EDECRIN",
        "Dosage Form": "Powder, for Injection Solution, Lyophilized",
        "Strength": "50 mg/vial",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "01/1967"
    },
    {
        "id": "380",
        "Proprietary Name": "EDECRIN",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "01/2016 - 01/2017"
    },
    {
        "id": "381",
        "Proprietary Name": "EFUDEX",
        "Dosage Form": "Cream",
        "Strength": "5%",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "07/2013"
    },
    {
        "id": "382",
        "Proprietary Name": "ELDEPRYL",
        "Dosage Form": "Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Somerset Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "05/1998 - 05/1999"
    },
    {
        "id": "383",
        "Proprietary Name": "ELDEPRYL",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Somerset Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/1999 - 06/2000"
    },
    {
        "id": "384",
        "Proprietary Name": "ELIDEL",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/2018"
    },
    {
        "id": "385",
        "Proprietary Name": "ELIMITE",
        "Dosage Form": "Cream",
        "Strength": "5%",
        "NDA Applicant Name": "Mylan Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2017"
    },
    {
        "id": "386",
        "Proprietary Name": "ELOXATIN",
        "Dosage Form": "Injection",
        "Strength": "100 mg / 20 mL (5 mg/mL)",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "387",
        "Proprietary Name": "ELOXATIN",
        "Dosage Form": "Injection",
        "Strength": "50 mg / 10 mL (5 mg/mL)",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "388",
        "Proprietary Name": "ELOXATIN (PREMIERPro)",
        "Dosage Form": "Injection",
        "Strength": "50 mg/10 mL (5 mg/mL)",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "389",
        "Proprietary Name": "ELOXATIN (PREMIERPro)",
        "Dosage Form": "Injection",
        "Strength": "100 mg / 20 mL (5 mg/mL)",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "390",
        "Proprietary Name": "EMLA",
        "Dosage Form": "Cream",
        "Strength": "2.5% and 2.5%",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "11/12/2012"
    },
    {
        "id": "391",
        "Proprietary Name": "ENTOCORT EC",
        "Dosage Form": "Capsules",
        "Strength": "3 mg",
        "NDA Applicant Name": "Padagis US LLC",
        "Date Authorized Generic Entered the Market": "08/18/2011"
    },
    {
        "id": "392",
        "Proprietary Name": "EPANED",
        "Dosage Form": "Oral Solution",
        "Strength": "1 mg/mL",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "03/2022"
    },
    {
        "id": "393",
        "Proprietary Name": "EPCLUSA",
        "Dosage Form": "Tablets",
        "Strength": "400 mg / 100 mg",
        "NDA Applicant Name": "Gilead Sciences, Inc.",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "394",
        "Proprietary Name": "EPIDUO",
        "Dosage Form": "Topical Gel",
        "Strength": "0.1% / 2.5%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "08/2017"
    },
    {
        "id": "395",
        "Proprietary Name": "EPIDUO FORTE",
        "Dosage Form": "Gel",
        "Strength": "0.3% and 2.5%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "02/2022"
    },
    {
        "id": "396",
        "Proprietary Name": "EPIPEN",
        "Dosage Form": "Injection",
        "Strength": "0.3 mg/0.3 mL",
        "NDA Applicant Name": "Mylan Specialty L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "12/15/2016"
    },
    {
        "id": "397",
        "Proprietary Name": "EPIPEN JR.",
        "Dosage Form": "Injection",
        "Strength": "0.15/0.3 mL",
        "NDA Applicant Name": "Mylan Specialty L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "12/15/2016"
    },
    {
        "id": "398",
        "Proprietary Name": "EPIVIR-HBV",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "GlaxoSmithKline LLC",
        "Date Authorized Generic Entered the Market": "09/05/2014"
    },
    {
        "id": "399",
        "Proprietary Name": "EPZICOM",
        "Dosage Form": "Tablets",
        "Strength": "600 mg and 300 mg",
        "NDA Applicant Name": "ViiV Healthcare Company",
        "Date Authorized Generic Entered the Market": "09/2016"
    },
    {
        "id": "400",
        "Proprietary Name": "ERYC",
        "Dosage Form": "Delayed- Release Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Dr. Reddy's Laboratories, SA",
        "Date Authorized Generic Entered the Market": "07/29/2013"
    },
    {
        "id": "401",
        "Proprietary Name": "ERYGEL",
        "Dosage Form": "Topical Gel",
        "Strength": "2%",
        "NDA Applicant Name": "Mylan Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/19/2018"
    },
    {
        "id": "402",
        "Proprietary Name": "ERYPED 200",
        "Dosage Form": "Suspension",
        "Strength": "200 mg per 5 mL when reconstituted",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "403",
        "Proprietary Name": "ERYPED 400",
        "Dosage Form": "Suspension",
        "Strength": "400 mg per 5 mL when reconstituted",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "404",
        "Proprietary Name": "EVOXAC",
        "Dosage Form": "Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Daiichi Sankyo, Inc.",
        "Date Authorized Generic Entered the Market": "03/2016"
    },
    {
        "id": "405",
        "Proprietary Name": "EXALGO",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "32 mg",
        "NDA Applicant Name": "SpecGx LLC",
        "Date Authorized Generic Entered the Market": "06/12/2014"
    },
    {
        "id": "406",
        "Proprietary Name": "EXALGO",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "12 mg",
        "NDA Applicant Name": "SpecGx LLC",
        "Date Authorized Generic Entered the Market": "06/12/2014"
    },
    {
        "id": "407",
        "Proprietary Name": "EXALGO",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "SpecGx LLC",
        "Date Authorized Generic Entered the Market": "06/12/2014"
    },
    {
        "id": "408",
        "Proprietary Name": "EXALGO",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "16 mg",
        "NDA Applicant Name": "SpecGx LLC",
        "Date Authorized Generic Entered the Market": "06/12/2014"
    },
    {
        "id": "409",
        "Proprietary Name": "EXELDERM",
        "Dosage Form": "Cream",
        "Strength": "1.0%",
        "NDA Applicant Name": "Journey Medical Corporation",
        "Date Authorized Generic Entered the Market": "02/2020"
    },
    {
        "id": "410",
        "Proprietary Name": "EXELDERM",
        "Dosage Form": "Solution",
        "Strength": "1.0%",
        "NDA Applicant Name": "Journey Medical Corporation",
        "Date Authorized Generic Entered the Market": "02/2020"
    },
    {
        "id": "411",
        "Proprietary Name": "EXELON",
        "Dosage Form": "Patch",
        "Strength": "4.6 mg/24 hours",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "412",
        "Proprietary Name": "EXELON",
        "Dosage Form": "Patch",
        "Strength": "9.5 mg/24 hours",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "413",
        "Proprietary Name": "EXELON",
        "Dosage Form": "Patch",
        "Strength": "13.3 mg/24 hours",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "414",
        "Proprietary Name": "EXTINA",
        "Dosage Form": "Aerosol Foam",
        "Strength": "2%",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "12/2018"
    },
    {
        "id": "415",
        "Proprietary Name": "FABIOR",
        "Dosage Form": "Aerosol Foam",
        "Strength": "0.1%",
        "NDA Applicant Name": "Mayne Pharma LLC",
        "Date Authorized Generic Entered the Market": "04/2021"
    },
    {
        "id": "416",
        "Proprietary Name": "FAMVIR",
        "Dosage Form": "Tablets",
        "Strength": "125 mg",
        "NDA Applicant Name": "Novartis",
        "Date Authorized Generic Entered the Market": "03/22/2011"
    },
    {
        "id": "417",
        "Proprietary Name": "FAMVIR",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Novartis",
        "Date Authorized Generic Entered the Market": "03/22/2011"
    },
    {
        "id": "418",
        "Proprietary Name": "FAMVIR FAMVIR",
        "Dosage Form": "Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Novartis",
        "Date Authorized Generic Entered the Market": "03/22/2011"
    },
    {
        "id": "419",
        "Proprietary Name": "FELBATOL",
        "Dosage Form": "Oral Suspension",
        "Strength": "600 mg/5 mL",
        "NDA Applicant Name": "Mylan Specialty, L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "1/2012"
    },
    {
        "id": "420",
        "Proprietary Name": "FELBATOL",
        "Dosage Form": "Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "Mylan Specialty, L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "11/2011"
    },
    {
        "id": "421",
        "Proprietary Name": "FELBATOL",
        "Dosage Form": "Tablets",
        "Strength": "600 mg",
        "NDA Applicant Name": "Mylan Specialty, L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "11/2011"
    },
    {
        "id": "422",
        "Proprietary Name": "FELDENE",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/03/2014"
    },
    {
        "id": "423",
        "Proprietary Name": "FELDENE",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/03/2014"
    },
    {
        "id": "424",
        "Proprietary Name": "FEMCON Fe",
        "Dosage Form": "Chewable Tablets",
        "Strength": "0.4 mg/35 mcg",
        "NDA Applicant Name": "Allergan Pharmaceuticals International Ltd.",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "425",
        "Proprietary Name": "FENOGLIDE",
        "Dosage Form": "Tablets",
        "Strength": "120 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/24/2015"
    },
    {
        "id": "426",
        "Proprietary Name": "FENOGLIDE",
        "Dosage Form": "Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/24/2015"
    },
    {
        "id": "427",
        "Proprietary Name": "FENOGLIDE",
        "Dosage Form": "Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "03/2021"
    },
    {
        "id": "428",
        "Proprietary Name": "FENOGLIDE",
        "Dosage Form": "Tablets",
        "Strength": "120 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "03/2021"
    },
    {
        "id": "429",
        "Proprietary Name": "FENTORA",
        "Dosage Form": "Tablet",
        "Strength": "800 mcg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "430",
        "Proprietary Name": "FENTORA",
        "Dosage Form": "Tablet",
        "Strength": "600 mcg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "431",
        "Proprietary Name": "FENTORA",
        "Dosage Form": "Tablet",
        "Strength": "200 mcg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "432",
        "Proprietary Name": "FENTORA",
        "Dosage Form": "Tablet",
        "Strength": "400 mcg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "433",
        "Proprietary Name": "FINACEA",
        "Dosage Form": "Gel",
        "Strength": "15%",
        "NDA Applicant Name": "LEO Pharma Inc.",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "434",
        "Proprietary Name": "FIORICET with CODEINE",
        "Dosage Form": "Capsules",
        "Strength": "50 mg / 325 mg / 40 mg / 30 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "10/01/2003"
    },
    {
        "id": "435",
        "Proprietary Name": "FIRAZYR",
        "Dosage Form": "Injection",
        "Strength": "30 mg / 3.0ML",
        "NDA Applicant Name": "Shire Human Genetic Therapies, Inc.",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "436",
        "Proprietary Name": "FLECTOR",
        "Dosage Form": "Topical System",
        "Strength": "1.3%",
        "NDA Applicant Name": "Institut Biochimique SA (IBSA)",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "437",
        "Proprietary Name": "FLECTOR",
        "Dosage Form": "Topical System",
        "Strength": "1.3%",
        "NDA Applicant Name": "Institut Biochimique SA (IBSA)",
        "Date Authorized Generic Entered the Market": "03/2019"
    },
    {
        "id": "438",
        "Proprietary Name": "FLEQSUVY",
        "Dosage Form": "Suspension",
        "Strength": "5 mg/mL",
        "NDA Applicant Name": "Azurity Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "04/01/2023"
    },
    {
        "id": "439",
        "Proprietary Name": "FLORONE",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Pharmacia and Upjohn Company",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "440",
        "Proprietary Name": "FLOVENT DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "50 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "10/30/2023"
    },
    {
        "id": "441",
        "Proprietary Name": "FLOVENT DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "250 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "10/30/2023"
    },
    {
        "id": "442",
        "Proprietary Name": "FLOVENT DISKUS",
        "Dosage Form": "Inhalation Powder",
        "Strength": "100 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "10/30/2023"
    },
    {
        "id": "443",
        "Proprietary Name": "FLOVENT HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "220 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "05/2022"
    },
    {
        "id": "444",
        "Proprietary Name": "FLOVENT HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "110 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "05/2022"
    },
    {
        "id": "445",
        "Proprietary Name": "FLOVENT HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "44 mcg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd England",
        "Date Authorized Generic Entered the Market": "05/2022"
    },
    {
        "id": "446",
        "Proprietary Name": "FLUMADINE",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Forest Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "09/2002 - 09/2003"
    },
    {
        "id": "447",
        "Proprietary Name": "FLUOXETINE",
        "Dosage Form": "Tablets",
        "Strength": "60 mg",
        "NDA Applicant Name": "Alvogen Group Holdings 3, LLC",
        "Date Authorized Generic Entered the Market": "09/2017"
    },
    {
        "id": "448",
        "Proprietary Name": "FML",
        "Dosage Form": "Ophthalmic Suspension",
        "Strength": "0.1%",
        "NDA Applicant Name": "Allergan, Inc.",
        "Date Authorized Generic Entered the Market": "10/1997"
    },
    {
        "id": "449",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "450",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "451",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "11/2014"
    },
    {
        "id": "452",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "02/2015"
    },
    {
        "id": "453",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "35 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "454",
        "Proprietary Name": "FOCALIN XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "06/2015"
    },
    {
        "id": "455",
        "Proprietary Name": "FORFIVO XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "450 mg",
        "NDA Applicant Name": "Alvogen Group Holdings 3, LLC",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "456",
        "Proprietary Name": "FORFIVO XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "450 mg",
        "NDA Applicant Name": "Alvogen Group Holdings 3, LLC",
        "Date Authorized Generic Entered the Market": "09/2018"
    },
    {
        "id": "457",
        "Proprietary Name": "FORTEO",
        "Dosage Form": "Injection Solution",
        "Strength": "560 mcg/2.24 mL (250 mcg/mL)",
        "NDA Applicant Name": "Eli Lilly and Company",
        "Date Authorized Generic Entered the Market": "11/17/2023"
    },
    {
        "id": "458",
        "Proprietary Name": "FORTESA",
        "Dosage Form": "Gel",
        "Strength": "10 mg testosterone/actuation",
        "NDA Applicant Name": "Endo Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/25/2014"
    },
    {
        "id": "459",
        "Proprietary Name": "FOSRENOL",
        "Dosage Form": "Chewable Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "08/30/2017"
    },
    {
        "id": "460",
        "Proprietary Name": "FOSRENOL",
        "Dosage Form": "Chewable Tablets",
        "Strength": "750 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "08/2017"
    },
    {
        "id": "461",
        "Proprietary Name": "FOSRENOL",
        "Dosage Form": "Chewable Tablets",
        "Strength": "1000 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "08/2017"
    },
    {
        "id": "462",
        "Proprietary Name": "FURADANTIN",
        "Dosage Form": "Oral Suspension",
        "Strength": "25 mg / 5 mL",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "12/2011 - 12/2012"
    },
    {
        "id": "463",
        "Proprietary Name": "GABITRIL",
        "Dosage Form": "Tablets",
        "Strength": "16 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "12/2012"
    },
    {
        "id": "464",
        "Proprietary Name": "GABITRIL",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Cephalon Inc.",
        "Date Authorized Generic Entered the Market": "12/26/2012"
    },
    {
        "id": "465",
        "Proprietary Name": "GABITRIL",
        "Dosage Form": "Tablets",
        "Strength": "12 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "12/2012"
    },
    {
        "id": "466",
        "Proprietary Name": "GABITRIL",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Cephalon, Inc",
        "Date Authorized Generic Entered the Market": "12/26/2012"
    },
    {
        "id": "467",
        "Proprietary Name": "GASTROCROM",
        "Dosage Form": "Oral Concentrate",
        "Strength": "100 mg/5 mL (ampule)",
        "NDA Applicant Name": "Mylan Specialty, L.P.",
        "Date Authorized Generic Entered the Market": "06/2015"
    },
    {
        "id": "468",
        "Proprietary Name": "GENERESS FE",
        "Dosage Form": "Chewable Tablets",
        "Strength": "0.8 mg/25 mcg",
        "NDA Applicant Name": "Allergan Pharmaceuticals International Ltd.",
        "Date Authorized Generic Entered the Market": "03/2015"
    },
    {
        "id": "469",
        "Proprietary Name": "GEODON",
        "Dosage Form": "Capsules",
        "Strength": "80 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "470",
        "Proprietary Name": "GEODON",
        "Dosage Form": "Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "471",
        "Proprietary Name": "GEODON",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "472",
        "Proprietary Name": "GEODON",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/15/2011"
    },
    {
        "id": "473",
        "Proprietary Name": "GLUCOTROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/11/2004"
    },
    {
        "id": "474",
        "Proprietary Name": "GLUCOTROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/11/2004"
    },
    {
        "id": "475",
        "Proprietary Name": "GLUCOTROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/11/2004"
    },
    {
        "id": "476",
        "Proprietary Name": "GLUMETZA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1000 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "06/2008"
    },
    {
        "id": "477",
        "Proprietary Name": "GLUMETZA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "06/2008"
    },
    {
        "id": "478",
        "Proprietary Name": "GOLYTELY",
        "Dosage Form": "Powder for Oral Solution",
        "Strength": "PEG-3350 17.6 mmol/L, sodium 125 mmol/L, sulfate 40 mmol/L, chloride 35 mmol/L, bicarbonate 20 mmol/L and potassium 10 mmol/L (per 4 liter jug w/water)",
        "NDA Applicant Name": "Braintree Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "07/2009"
    },
    {
        "id": "479",
        "Proprietary Name": "GOPRELTO",
        "Dosage Form": "Solution",
        "Strength": "4%",
        "NDA Applicant Name": "Genus Lifesciences Inc.",
        "Date Authorized Generic Entered the Market": "06/2018"
    },
    {
        "id": "480",
        "Proprietary Name": "GRIS-PEG",
        "Dosage Form": "Tablets",
        "Strength": "125 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/03/2012"
    },
    {
        "id": "481",
        "Proprietary Name": "GRIS-PEG",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/03/2012"
    },
    {
        "id": "482",
        "Proprietary Name": "HALCION",
        "Dosage Form": "Tablets",
        "Strength": "0.125 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "7/11/2003"
    },
    {
        "id": "483",
        "Proprietary Name": "HALCION",
        "Dosage Form": "Tablets",
        "Strength": "0.25 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "6/17/2003"
    },
    {
        "id": "484",
        "Proprietary Name": "HALDOL DECANOATE",
        "Dosage Form": "Injection",
        "Strength": "100 mg/mL",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "07/2011"
    },
    {
        "id": "485",
        "Proprietary Name": "HALDOL DECANOATE",
        "Dosage Form": "Injection",
        "Strength": "50 mg/mL",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "08/2011"
    },
    {
        "id": "486",
        "Proprietary Name": "HARVONI",
        "Dosage Form": "Tablets",
        "Strength": "90 mg and 400 mg",
        "NDA Applicant Name": "Gilead Sciences, Inc.",
        "Date Authorized Generic Entered the Market": "01/2019"
    },
    {
        "id": "487",
        "Proprietary Name": "HECTOROL",
        "Dosage Form": "Capsules, liquid filled",
        "Strength": "0.5 mcg",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "03/11/2014"
    },
    {
        "id": "488",
        "Proprietary Name": "HECTOROL",
        "Dosage Form": "Capsules, liquid filled",
        "Strength": "1 mcg",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "03/11/2014"
    },
    {
        "id": "489",
        "Proprietary Name": "HECTOROL",
        "Dosage Form": "Capsules, liquid filled",
        "Strength": "2.5 mcg",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "03/11/2014"
    },
    {
        "id": "490",
        "Proprietary Name": "IMITREX",
        "Dosage Form": "Injection",
        "Strength": "6 mg/0.5 mL",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "491",
        "Proprietary Name": "IMITREX",
        "Dosage Form": "Injection",
        "Strength": "4 mg/0.5 mL",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "492",
        "Proprietary Name": "IMITREX",
        "Dosage Form": "Nasal Spray",
        "Strength": "5 mg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd. England",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "493",
        "Proprietary Name": "IMITREX",
        "Dosage Form": "Nasal Spray",
        "Strength": "20 mg",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Ltd. England",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "494",
        "Proprietary Name": "IMITREX (refill)",
        "Dosage Form": "Injection",
        "Strength": "6 mg/0.5 mL",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "495",
        "Proprietary Name": "IMITREX (refill)",
        "Dosage Form": "Injection",
        "Strength": "4 mg/0.5 mL",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Prop. Ltd. England",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "496",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "120 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "497",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "498",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "80 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "499",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "160 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "500",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "2/25/2009"
    },
    {
        "id": "501",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "80 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "2/25/2009"
    },
    {
        "id": "502",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "120 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "2/25/2009"
    },
    {
        "id": "503",
        "Proprietary Name": "INDERAL LA",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "160 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "2/25/2009"
    },
    {
        "id": "504",
        "Proprietary Name": "INSPRA",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "09/13/2007"
    },
    {
        "id": "505",
        "Proprietary Name": "INSPRA",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "09/13/2007"
    },
    {
        "id": "506",
        "Proprietary Name": "INVANZ",
        "Dosage Form": "Injection, Powder, Lyophylized, for Solution",
        "Strength": "1 g",
        "NDA Applicant Name": "Merck Sharp & Dohme Corp.",
        "Date Authorized Generic Entered the Market": "07/2018"
    },
    {
        "id": "507",
        "Proprietary Name": "INVEGA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1.5 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "09/24/2015"
    },
    {
        "id": "508",
        "Proprietary Name": "INVEGA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "3 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "09/24/2015"
    },
    {
        "id": "509",
        "Proprietary Name": "INVEGA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "6 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "09/24/2015"
    },
    {
        "id": "510",
        "Proprietary Name": "INVEGA",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "9 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "09/24/2015"
    },
    {
        "id": "511",
        "Proprietary Name": "IOPIDINE",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Harrow Eye, LLC",
        "Date Authorized Generic Entered the Market": "08/2009"
    },
    {
        "id": "512",
        "Proprietary Name": "ISOPTO CARPINE",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "2%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "02/21/1996"
    },
    {
        "id": "513",
        "Proprietary Name": "ISOPTO CARPINE",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "02/21/1996"
    },
    {
        "id": "514",
        "Proprietary Name": "ISOPTO CARPINE",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "4%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "02/21/1996"
    },
    {
        "id": "515",
        "Proprietary Name": "ISORDIL TITRADOSE",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "516",
        "Proprietary Name": "ISORDIL TITRADOSE",
        "Dosage Form": "Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "517",
        "Proprietary Name": "ISTALOL",
        "Dosage Form": "Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "05/2018"
    },
    {
        "id": "518",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "80 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "519",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "520",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "521",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "522",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "523",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "524",
        "Proprietary Name": "KADIAN",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "11/11/2011"
    },
    {
        "id": "525",
        "Proprietary Name": "KAZANO",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg/500 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "526",
        "Proprietary Name": "KAZANO",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg/1000 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "527",
        "Proprietary Name": "K-DUR 10",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mEq",
        "NDA Applicant Name": "Schering Corporation",
        "Date Authorized Generic Entered the Market": "06/2002 - 06/2003"
    },
    {
        "id": "528",
        "Proprietary Name": "K-DUR 20",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "20 mEq",
        "NDA Applicant Name": "Schering Corporation",
        "Date Authorized Generic Entered the Market": "06/1998 - 06/1999"
    },
    {
        "id": "529",
        "Proprietary Name": "KITABIS PAK",
        "Dosage Form": "Inhalation Solution",
        "Strength": "300 mg/5 mL ampules",
        "NDA Applicant Name": "PulmoFlow Inc.",
        "Date Authorized Generic Entered the Market": "07/2016"
    },
    {
        "id": "530",
        "Proprietary Name": "KLARON",
        "Dosage Form": "Lotion",
        "Strength": "10%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/2005 - 12/2006"
    },
    {
        "id": "531",
        "Proprietary Name": "K-TAB",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "8 mEq (600 mg)",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "02/2011"
    },
    {
        "id": "532",
        "Proprietary Name": "K-TAB",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mEq (750 mg)",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "02/2011"
    },
    {
        "id": "533",
        "Proprietary Name": "K-TAB",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "20 mEq (1500 mg)",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "01/2014"
    },
    {
        "id": "534",
        "Proprietary Name": "LAC-HYDRIN",
        "Dosage Form": "Cream",
        "Strength": "eq. 12% base",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "07/2004 - 06/2005"
    },
    {
        "id": "535",
        "Proprietary Name": "LAC-HYDRIN",
        "Dosage Form": "Lotion",
        "Strength": "eq. 12% base",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "03/2004 - 02/2005"
    },
    {
        "id": "536",
        "Proprietary Name": "LESCOL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "05/2018"
    },
    {
        "id": "537",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "125 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "538",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "539",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "540",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "541",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "175 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "542",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "137 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "543",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "112 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "544",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "545",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "546",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "88 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "547",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "75 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "548",
        "Proprietary Name": "LEVO-T",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "CEDIPROF, Inc.",
        "Date Authorized Generic Entered the Market": "08/2020"
    },
    {
        "id": "549",
        "Proprietary Name": "LEXETTE",
        "Dosage Form": "Foam",
        "Strength": "0.05%",
        "NDA Applicant Name": "Mayne Pharma LLC",
        "Date Authorized Generic Entered the Market": "02/2019"
    },
    {
        "id": "550",
        "Proprietary Name": "LIBRAX",
        "Dosage Form": "Capsules",
        "Strength": "5 mg/2.5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "09/2016 - 08/2017"
    },
    {
        "id": "551",
        "Proprietary Name": "LIDEX",
        "Dosage Form": "Topical Solution",
        "Strength": "0.05%",
        "NDA Applicant Name": "County Line Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "03/2018"
    },
    {
        "id": "552",
        "Proprietary Name": "LIDODERM",
        "Dosage Form": "Patch",
        "Strength": "700 mg (50 mg per gram adhesive) in an aqueous base",
        "NDA Applicant Name": "Teikoku Pharma USA, Inc.",
        "Date Authorized Generic Entered the Market": "05/2014"
    },
    {
        "id": "553",
        "Proprietary Name": "LIMBITROL",
        "Dosage Form": "Tablets",
        "Strength": "5 mg; eq. 12.5 mg base",
        "NDA Applicant Name": "Valeant Pharmaceuticals International",
        "Date Authorized Generic Entered the Market": "01/2006 - 12/2006"
    },
    {
        "id": "554",
        "Proprietary Name": "LIMBITROL DS",
        "Dosage Form": "Tablets",
        "Strength": "10 mg; eq. 25 mg base",
        "NDA Applicant Name": "Valeant Pharmaceuticals International",
        "Date Authorized Generic Entered the Market": "01/2007 - 12/2007"
    },
    {
        "id": "555",
        "Proprietary Name": "LIPOFEN",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Cipher Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "556",
        "Proprietary Name": "LIPOFEN",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Cipher Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "557",
        "Proprietary Name": "LITHOBID",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "558",
        "Proprietary Name": "LOCOID",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "Bausch Health U.S., LLC",
        "Date Authorized Generic Entered the Market": "07/2013"
    },
    {
        "id": "559",
        "Proprietary Name": "LOCOID",
        "Dosage Form": "Lotion",
        "Strength": "0.1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "06/2018"
    },
    {
        "id": "560",
        "Proprietary Name": "LOCOID (Ointment)",
        "Dosage Form": "Ointment",
        "Strength": "0.1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "10/2015 - 10/2016"
    },
    {
        "id": "561",
        "Proprietary Name": "LOCOID LIPOCREAM",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/03/2013"
    },
    {
        "id": "562",
        "Proprietary Name": "LODOSYN",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "563",
        "Proprietary Name": "LOMOTIL",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg/0.025 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "07/2011, 02/2013"
    },
    {
        "id": "564",
        "Proprietary Name": "LOPRESSOR HCT",
        "Dosage Form": "Tablets",
        "Strength": "1 mg/mL",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "03/1998 - 03/1999"
    },
    {
        "id": "565",
        "Proprietary Name": "LOPRESSOR HCT",
        "Dosage Form": "Tablets",
        "Strength": "50mg / 25mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "11/25/2009"
    },
    {
        "id": "566",
        "Proprietary Name": "LOPRESSOR HCT",
        "Dosage Form": "Tablets",
        "Strength": "100 mg / 25 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "11/25/2009"
    },
    {
        "id": "567",
        "Proprietary Name": "LOPROX",
        "Dosage Form": "Cream",
        "Strength": "0.77%",
        "NDA Applicant Name": "Medicis Pharmaceutical Corporation",
        "Date Authorized Generic Entered the Market": "12/2004 - 11/2005"
    },
    {
        "id": "568",
        "Proprietary Name": "LOPROX",
        "Dosage Form": "Gel",
        "Strength": "0.77%",
        "NDA Applicant Name": "Alvogen, Inc.",
        "Date Authorized Generic Entered the Market": "07/2007 - 06/2008"
    },
    {
        "id": "569",
        "Proprietary Name": "LOPROX",
        "Dosage Form": "Shampoo",
        "Strength": "1%",
        "NDA Applicant Name": "Medicis Pharmaceutical Corporation",
        "Date Authorized Generic Entered the Market": "12/2012"
    },
    {
        "id": "570",
        "Proprietary Name": "LoSEASONIQUE",
        "Dosage Form": "Tablets",
        "Strength": "0.1 mg/0.02 mg and 0.01 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "12/07/2011"
    },
    {
        "id": "571",
        "Proprietary Name": "LoSEASONIQUE",
        "Dosage Form": "Tablets",
        "Strength": "0.1 mg/0.02 mg and 0.01 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "11/10/2016"
    },
    {
        "id": "572",
        "Proprietary Name": "LOTEMAX",
        "Dosage Form": "Ophthalmic Suspension",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "573",
        "Proprietary Name": "LOTENSIN HCT",
        "Dosage Form": "Tablets",
        "Strength": "10 mg; 12.5 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "574",
        "Proprietary Name": "LOTENSIN HCT",
        "Dosage Form": "Tablets",
        "Strength": "20 mg; 12.5 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "575",
        "Proprietary Name": "LOTENSIN HCT",
        "Dosage Form": "Tablets",
        "Strength": "20 mg; 25 mg",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "576",
        "Proprietary Name": "LOTRIMIN AF",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Schering-Plough HealthCare Products, Inc",
        "Date Authorized Generic Entered the Market": "03/1998 - 03/1999"
    },
    {
        "id": "577",
        "Proprietary Name": "LOTRONEX",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Sebela Ireland Limited",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "578",
        "Proprietary Name": "LOTRONEX",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Sebela Ireland Limited",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "579",
        "Proprietary Name": "LOTRONEX",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Sebela Ireland Limited",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "580",
        "Proprietary Name": "LOTRONEX",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Sebela Ireland Limited",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "581",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "150 mg/1 mL graduated prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "582",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "30 mg/0.3 mL prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "583",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "120 mg/0.8 mL graduated prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "584",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "80 mg/0.8 mL graduated prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "585",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "40 mg/0.4 mL prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "586",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "300 mg/3 mL multi-dose vial",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "587",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "100 mg/1 mL graduated prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "588",
        "Proprietary Name": "LOVENOX",
        "Dosage Form": "Injection",
        "Strength": "60 mg/0.6 mL graduated prefilled syringe",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "589",
        "Proprietary Name": "LOZOL",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Rhone-Poulenc Rorer Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "590",
        "Proprietary Name": "LUVOX",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2011"
    },
    {
        "id": "591",
        "Proprietary Name": "LUVOX",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2011"
    },
    {
        "id": "592",
        "Proprietary Name": "LUVOX",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2011"
    },
    {
        "id": "593",
        "Proprietary Name": "LUZU",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2018"
    },
    {
        "id": "594",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "595",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "596",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "597",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "598",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "599",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "600",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "225 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "601",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Capsules",
        "Strength": "75 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "602",
        "Proprietary Name": "LYRICA",
        "Dosage Form": "Oral Solution",
        "Strength": "20 mg/mL",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "603",
        "Proprietary Name": "LYSTEDA",
        "Dosage Form": "Tablets",
        "Strength": "650 mg",
        "NDA Applicant Name": "Amring Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "03/17/2016"
    },
    {
        "id": "604",
        "Proprietary Name": "MACROBID",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "02/2011"
    },
    {
        "id": "605",
        "Proprietary Name": "MACRODANTIN",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "08/2011"
    },
    {
        "id": "606",
        "Proprietary Name": "MACRODANTIN",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "08/2011"
    },
    {
        "id": "607",
        "Proprietary Name": "MACRODANTIN",
        "Dosage Form": "Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "09/2010"
    },
    {
        "id": "608",
        "Proprietary Name": "MALARONE",
        "Dosage Form": "Tablets",
        "Strength": "250 mg/100 mg",
        "NDA Applicant Name": "GlaxoSmithKline LLC",
        "Date Authorized Generic Entered the Market": "7/31/2012"
    },
    {
        "id": "609",
        "Proprietary Name": "MARINOL",
        "Dosage Form": "Capsules",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "610",
        "Proprietary Name": "MARINOL",
        "Dosage Form": "Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "611",
        "Proprietary Name": "MARINOL",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "612",
        "Proprietary Name": "MAXIMUM STRENGTH MUCINEX DM",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1200 mg and 60 mg",
        "NDA Applicant Name": "RB Health (US) LLC",
        "Date Authorized Generic Entered the Market": "09/2017"
    },
    {
        "id": "613",
        "Proprietary Name": "MAXIMUM STRENGTH MUCINEX DM",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1200 mg and 60 mg",
        "NDA Applicant Name": "RB Health (US) LLC",
        "Date Authorized Generic Entered the Market": "10/2017"
    },
    {
        "id": "614",
        "Proprietary Name": "MAXIMUM STRENGTH MUCINEX DM",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1200 mg and 60 mg",
        "NDA Applicant Name": "RB Health (US) LLC",
        "Date Authorized Generic Entered the Market": "09/2017"
    },
    {
        "id": "615",
        "Proprietary Name": "MAXITROL",
        "Dosage Form": "Ophthalmic Ointment",
        "Strength": "3.5 mg and 10000 units and 0.1% / gram",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "03/04/1996"
    },
    {
        "id": "616",
        "Proprietary Name": "MAXZIDE",
        "Dosage Form": "Tablets",
        "Strength": "75 mg and 50 mg",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "617",
        "Proprietary Name": "MAXZIDE-25",
        "Dosage Form": "Tablets",
        "Strength": "37.5 mg and 25 mg",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "618",
        "Proprietary Name": "MEDROL",
        "Dosage Form": "Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "4/22/2013"
    },
    {
        "id": "619",
        "Proprietary Name": "MEDROL",
        "Dosage Form": "Tablets",
        "Strength": "16 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "4/22/2013"
    },
    {
        "id": "620",
        "Proprietary Name": "MEDROL",
        "Dosage Form": "Tablets",
        "Strength": "32 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "4/22/2013"
    },
    {
        "id": "621",
        "Proprietary Name": "MEDROL",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "11/16/2011"
    },
    {
        "id": "622",
        "Proprietary Name": "MEGACE ES",
        "Dosage Form": "Oral Suspension",
        "Strength": "625 mg/5 mL (125 mg/mL)",
        "NDA Applicant Name": "Endo Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "07/2015"
    },
    {
        "id": "623",
        "Proprietary Name": "MELOXICAM",
        "Dosage Form": "Oral Suspension",
        "Strength": "7.5 mg / 5 mL",
        "NDA Applicant Name": "Avondale Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "06/29/2022"
    },
    {
        "id": "624",
        "Proprietary Name": "MEPHYTON",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "04/23/2018"
    },
    {
        "id": "625",
        "Proprietary Name": "MESNEX",
        "Dosage Form": "Injection",
        "Strength": "100 mg/mL",
        "NDA Applicant Name": "Baxter Healthcare Corporation",
        "Date Authorized Generic Entered the Market": "12/2003 - 12/2004"
    },
    {
        "id": "626",
        "Proprietary Name": "MESTINON",
        "Dosage Form": "Oral Solution",
        "Strength": "60 mg / 5 mL",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "627",
        "Proprietary Name": "MESTINON",
        "Dosage Form": "Tablets",
        "Strength": "60 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "04/2002 - 03/2003"
    },
    {
        "id": "628",
        "Proprietary Name": "MESTINON TIMESPAN",
        "Dosage Form": "Tablets",
        "Strength": "180 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "11/2015"
    },
    {
        "id": "629",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "630",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "60 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "631",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "632",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "633",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "634",
        "Proprietary Name": "METADATE CD",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2012"
    },
    {
        "id": "635",
        "Proprietary Name": "METHYLIN",
        "Dosage Form": "Oral Solution",
        "Strength": "5 mg/5 mL",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "08/01/2013"
    },
    {
        "id": "636",
        "Proprietary Name": "METHYLIN",
        "Dosage Form": "Oral Solution",
        "Strength": "10 mg/5 mL",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "08/01/2013"
    },
    {
        "id": "637",
        "Proprietary Name": "METROCREAM",
        "Dosage Form": "Cream",
        "Strength": "0.75%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "3/2009"
    },
    {
        "id": "638",
        "Proprietary Name": "METROGEL",
        "Dosage Form": "Gel",
        "Strength": "1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "02/2017"
    },
    {
        "id": "639",
        "Proprietary Name": "METROGEL",
        "Dosage Form": "Gel",
        "Strength": "0.75%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "03/2014"
    },
    {
        "id": "640",
        "Proprietary Name": "METROGEL",
        "Dosage Form": "Gel",
        "Strength": "1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "11/10/2023"
    },
    {
        "id": "641",
        "Proprietary Name": "METROGEL VAGINAL GEL",
        "Dosage Form": "Vaginal Gel",
        "Strength": "0.75%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2015"
    },
    {
        "id": "642",
        "Proprietary Name": "METROLOTION",
        "Dosage Form": "Lotion",
        "Strength": "0.75%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "6/16/2009"
    },
    {
        "id": "643",
        "Proprietary Name": "MIACALCIN",
        "Dosage Form": "Nasal Spray",
        "Strength": "200 I.U. per actuation",
        "NDA Applicant Name": "Sebela Ireland Ltd.",
        "Date Authorized Generic Entered the Market": "12/09/2008"
    },
    {
        "id": "644",
        "Proprietary Name": "MICRONASE",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "645",
        "Proprietary Name": "MICRONASE",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "646",
        "Proprietary Name": "MICROZIDE",
        "Dosage Form": "Capsules",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "10/05/2001"
    },
    {
        "id": "647",
        "Proprietary Name": "MIDAMOR",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Padagis US LLC",
        "Date Authorized Generic Entered the Market": "04/06/2009"
    },
    {
        "id": "648",
        "Proprietary Name": "MIGRANAL",
        "Dosage Form": "Nasal Spray",
        "Strength": "4 mg in 1 mL",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/18/2013"
    },
    {
        "id": "649",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "1 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "650",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "651",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "2 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "652",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/2022"
    },
    {
        "id": "653",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "1 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "08/2021"
    },
    {
        "id": "654",
        "Proprietary Name": "MINIPRESS",
        "Dosage Form": "Capsules",
        "Strength": "2 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "03/2022"
    },
    {
        "id": "655",
        "Proprietary Name": "MINIVELLE",
        "Dosage Form": "Film, Extended Release",
        "Strength": "0.075 mg per day",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "656",
        "Proprietary Name": "MINIVELLE",
        "Dosage Form": "Film, Extended Release",
        "Strength": "0.05 mg per day",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "657",
        "Proprietary Name": "MINIVELLE",
        "Dosage Form": "Film, Extended Release",
        "Strength": "0.025 mg per day",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "658",
        "Proprietary Name": "MINIVELLE",
        "Dosage Form": "Film, Extended Release",
        "Strength": "0.0375 mg per day",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "659",
        "Proprietary Name": "MINIVELLE",
        "Dosage Form": "Film, Extended Release",
        "Strength": "0.1 mg per day",
        "NDA Applicant Name": "Noven Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "660",
        "Proprietary Name": "MITIGARE",
        "Dosage Form": "Capsules",
        "Strength": "0.6 mg",
        "NDA Applicant Name": "Hikma International Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "10/01/2014"
    },
    {
        "id": "661",
        "Proprietary Name": "MONODOX",
        "Dosage Form": "Capsules",
        "Strength": "75 mg",
        "NDA Applicant Name": "Aqua Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "10/2014"
    },
    {
        "id": "662",
        "Proprietary Name": "MONODOX",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Aqua Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "02/07/2005"
    },
    {
        "id": "663",
        "Proprietary Name": "MONODOX",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Aqua Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "02/07/2005"
    },
    {
        "id": "664",
        "Proprietary Name": "MONOKET",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "ECI Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "06/30/1996 - 06/29/1997"
    },
    {
        "id": "665",
        "Proprietary Name": "MONUROL",
        "Dosage Form": "Granules for Oral Solution",
        "Strength": "3 g",
        "NDA Applicant Name": "Zambon S.p.A.",
        "Date Authorized Generic Entered the Market": "01/27/2022"
    },
    {
        "id": "666",
        "Proprietary Name": "MOVIPREP",
        "Dosage Form": "Powder for Oral Solution",
        "Strength": "100 g/7.5 g/2.691 g/1.015 g/5.9 g/4.7 g",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "09/2020"
    },
    {
        "id": "667",
        "Proprietary Name": "MOXATAG",
        "Dosage Form": "Extended- Release Tablets",
        "Strength": "775 mg",
        "NDA Applicant Name": "Vernalis (R&D) Limited",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "668",
        "Proprietary Name": "MOZOBIL",
        "Dosage Form": "Injection, Solution",
        "Strength": "24 mg/1.2 mL",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "7/24/2023"
    },
    {
        "id": "669",
        "Proprietary Name": "MS CONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "15 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "05/2005 - 05/2006"
    },
    {
        "id": "670",
        "Proprietary Name": "MS CONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "30 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "05/2005 - 05/2006"
    },
    {
        "id": "671",
        "Proprietary Name": "MS CONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "60 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "05/2005 - 05/2006"
    },
    {
        "id": "672",
        "Proprietary Name": "MS CONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "05/2005 - 05/2006"
    },
    {
        "id": "673",
        "Proprietary Name": "MS CONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "05/2005 - 05/2006"
    },
    {
        "id": "674",
        "Proprietary Name": "MUCINEX",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "600 mg",
        "NDA Applicant Name": "RB Health (US), LLC",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "675",
        "Proprietary Name": "MYAMBUTOL",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "STI Pharma LLC",
        "Date Authorized Generic Entered the Market": "12/15/2006"
    },
    {
        "id": "676",
        "Proprietary Name": "MYAMBUTOL",
        "Dosage Form": "Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "STI Pharma LLC",
        "Date Authorized Generic Entered the Market": "12/15/2006"
    },
    {
        "id": "677",
        "Proprietary Name": "MYCOBUTIN",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "05/13/2014"
    },
    {
        "id": "678",
        "Proprietary Name": "MYSOLINE",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "05/2018"
    },
    {
        "id": "679",
        "Proprietary Name": "MYSOLINE",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "05/2018"
    },
    {
        "id": "680",
        "Proprietary Name": "NALFON",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Xspire Pharma LLC",
        "Date Authorized Generic Entered the Market": "08/05/2015"
    },
    {
        "id": "681",
        "Proprietary Name": "NALFON",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Xspire Pharma LLC",
        "Date Authorized Generic Entered the Market": "05/2016"
    },
    {
        "id": "682",
        "Proprietary Name": "NALFON",
        "Dosage Form": "Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Xspire Pharma LLC",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "683",
        "Proprietary Name": "NAMENDA",
        "Dosage Form": "Tablets",
        "Strength": "5 mg and 10 mg (titration pak)",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2015"
    },
    {
        "id": "684",
        "Proprietary Name": "NAMENDA",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2015"
    },
    {
        "id": "685",
        "Proprietary Name": "NAMENDA",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "04/01/2015"
    },
    {
        "id": "686",
        "Proprietary Name": "NAPRELAN",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "375 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "687",
        "Proprietary Name": "NAPRELAN",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "750 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "03/2015"
    },
    {
        "id": "688",
        "Proprietary Name": "NAPRELAN",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Almatica Pharma LLC",
        "Date Authorized Generic Entered the Market": "03/2015"
    },
    {
        "id": "689",
        "Proprietary Name": "NAPROSYN",
        "Dosage Form": "Suspension",
        "Strength": "125 mg/5 mL",
        "NDA Applicant Name": "Atnahs Pharma US Limited",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "690",
        "Proprietary Name": "NAPROSYN EC (EC- NAPROSYN)",
        "Dosage Form": "Delayed- Release Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Atnahs Pharma US Limited",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "691",
        "Proprietary Name": "NARDIL",
        "Dosage Form": "Tablets",
        "Strength": "15 mg",
        "NDA Applicant Name": "Parke-Davis",
        "Date Authorized Generic Entered the Market": "3/23/2011"
    },
    {
        "id": "692",
        "Proprietary Name": "NASACORT AQ",
        "Dosage Form": "Nasal Spray Spray Bottle",
        "Strength": "55 mcg/spray",
        "NDA Applicant Name": "Sanofi Aventis US, LLC",
        "Date Authorized Generic Entered the Market": "06/15/2011"
    },
    {
        "id": "693",
        "Proprietary Name": "NATROBA",
        "Dosage Form": "Topical Suspension",
        "Strength": "0.9%",
        "NDA Applicant Name": "ParaPRO LLC",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "694",
        "Proprietary Name": "NEOPROFEN",
        "Dosage Form": "Injection",
        "Strength": "20mg/2mL (10mg/mL)",
        "NDA Applicant Name": "Recordati Rare Diseases Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "695",
        "Proprietary Name": "NESINA",
        "Dosage Form": "Tablets",
        "Strength": "6.25 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "696",
        "Proprietary Name": "NESINA",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "697",
        "Proprietary Name": "NESINA",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "698",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "3/17/2004"
    },
    {
        "id": "699",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "03/17/2004"
    },
    {
        "id": "700",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "3/17/2004"
    },
    {
        "id": "701",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Oral Solution",
        "Strength": "250 mg per 5 mL",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "3/24/2011"
    },
    {
        "id": "702",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Tablets",
        "Strength": "600 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "3/17/2004"
    },
    {
        "id": "703",
        "Proprietary Name": "NEURONTIN",
        "Dosage Form": "Tablets",
        "Strength": "800 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "3/17/2004"
    },
    {
        "id": "704",
        "Proprietary Name": "NIASPAN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "06/30/2014"
    },
    {
        "id": "705",
        "Proprietary Name": "NIASPAN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "750 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "06/30/2014"
    },
    {
        "id": "706",
        "Proprietary Name": "NIASPAN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1000 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "06/30/2014"
    },
    {
        "id": "707",
        "Proprietary Name": "NICORETTE",
        "Dosage Form": "Chewing Gum",
        "Strength": "2 mg",
        "NDA Applicant Name": "GlaxoSmithKline Consumer Healthcare L.P.",
        "Date Authorized Generic Entered the Market": "01/2002 - 01/2003"
    },
    {
        "id": "708",
        "Proprietary Name": "NICORETTE",
        "Dosage Form": "Chewing Gum",
        "Strength": "4 mg",
        "NDA Applicant Name": "GlaxoSmithKline Consumer Healthcare L.P.",
        "Date Authorized Generic Entered the Market": "06/2001 - 06/2002"
    },
    {
        "id": "709",
        "Proprietary Name": "NILANDRON",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "11/2019"
    },
    {
        "id": "710",
        "Proprietary Name": "NITRO-DUR",
        "Dosage Form": "Transdermal",
        "Strength": "0.4 mg/hr",
        "NDA Applicant Name": "USpharma Ltd.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "711",
        "Proprietary Name": "NITRO-DUR",
        "Dosage Form": "Transdermal",
        "Strength": "0.2 mg/hr",
        "NDA Applicant Name": "USpharma Ltd.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "712",
        "Proprietary Name": "NITRO-DUR",
        "Dosage Form": "Transdermal",
        "Strength": "0.6 mg/hr",
        "NDA Applicant Name": "USpharma Ltd.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "713",
        "Proprietary Name": "NITRO-DUR",
        "Dosage Form": "Transdermal",
        "Strength": "0.1 mg/hr",
        "NDA Applicant Name": "USpharma Ltd.",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "714",
        "Proprietary Name": "NITROLINGUAL PUMPSPRAY",
        "Dosage Form": "Lingual Spray",
        "Strength": "400 mcg per Spray",
        "NDA Applicant Name": "G. Pohl-Boskamp GmbH & Co.",
        "Date Authorized Generic Entered the Market": "02/01/2011"
    },
    {
        "id": "715",
        "Proprietary Name": "NITROSTAT",
        "Dosage Form": "Tablets",
        "Strength": "0.6 mg",
        "NDA Applicant Name": "Viatris Speciality LLC",
        "Date Authorized Generic Entered the Market": "08/26/2016"
    },
    {
        "id": "716",
        "Proprietary Name": "NITROSTAT",
        "Dosage Form": "Tablets",
        "Strength": "0.4 mg",
        "NDA Applicant Name": "Viatris Speciality LLC",
        "Date Authorized Generic Entered the Market": "08/26/2016"
    },
    {
        "id": "717",
        "Proprietary Name": "NITROSTAT",
        "Dosage Form": "Tablets",
        "Strength": "0.3 mg",
        "NDA Applicant Name": "Viatris Speciality LLC",
        "Date Authorized Generic Entered the Market": "08/26/2016"
    },
    {
        "id": "718",
        "Proprietary Name": "NORPACE",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "719",
        "Proprietary Name": "NORPACE",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "720",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "721",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "722",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "723",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "724",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "75 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "725",
        "Proprietary Name": "NORPRAMIN",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Sanofi-Aventis US LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "726",
        "Proprietary Name": "NOR-QD",
        "Dosage Form": "Tablets",
        "Strength": "0.35 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceuticals Products R&D, Inc",
        "Date Authorized Generic Entered the Market": "06/06/2003"
    },
    {
        "id": "727",
        "Proprietary Name": "NORVASC",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "6/15/2006"
    },
    {
        "id": "728",
        "Proprietary Name": "NORVASC",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "6/15/2006"
    },
    {
        "id": "729",
        "Proprietary Name": "NORVASC",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "6/15/2006"
    },
    {
        "id": "730",
        "Proprietary Name": "NOXAFIL",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Merck Sharp & Dohme Corp.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "731",
        "Proprietary Name": "NOXAFIL",
        "Dosage Form": "Oral Suspension",
        "Strength": "40 mg/mL",
        "NDA Applicant Name": "Merck Sharp & Dohme LLC, a subsidary of Merck & Co., Inc.",
        "Date Authorized Generic Entered the Market": "3/29/2023"
    },
    {
        "id": "732",
        "Proprietary Name": "NULYTELY",
        "Dosage Form": "Powder (for reconstitution with water)",
        "Strength": "Per 4 liter jug: polyethylene glycol 3350 420 g, sodium bicarbonate 5.72 g, sodium chloride 11.2 g, potassium chloride 1.48 g, flavoring 2 g",
        "NDA Applicant Name": "Braintree Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "02/2013"
    },
    {
        "id": "733",
        "Proprietary Name": "NUMBRINO",
        "Dosage Form": "Nasal Solution",
        "Strength": "4%",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "09/2020"
    },
    {
        "id": "734",
        "Proprietary Name": "NUVARING",
        "Dosage Form": "Vaginal Ring",
        "Strength": "11.7 mg / 2.7 mg (delivers 0.12 mg/0.015 mg per day)",
        "NDA Applicant Name": "Organon USA LLC",
        "Date Authorized Generic Entered the Market": "12/2019"
    },
    {
        "id": "735",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "736",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "737",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "738",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "739",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "740",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "741",
        "Proprietary Name": "NUVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Teva Pharmaceuticals USA",
        "Date Authorized Generic Entered the Market": "12/2016"
    },
    {
        "id": "742",
        "Proprietary Name": "OLUX",
        "Dosage Form": "Foam",
        "Strength": "0.05%",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "12/2018"
    },
    {
        "id": "743",
        "Proprietary Name": "OLUX-E",
        "Dosage Form": "Emulsion, Aerosol Foam",
        "Strength": "0.05%",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc., a Viatris Company",
        "Date Authorized Generic Entered the Market": "01/2019"
    },
    {
        "id": "744",
        "Proprietary Name": "OMNIPRED",
        "Dosage Form": "Ophthalmic Suspension",
        "Strength": "1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/1995"
    },
    {
        "id": "745",
        "Proprietary Name": "OPTIVAR",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.05%",
        "NDA Applicant Name": "Meda Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "03/10/2011"
    },
    {
        "id": "746",
        "Proprietary Name": "ORABLOC",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Pierrel S.p.A.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "747",
        "Proprietary Name": "ORABLOC",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:200,000",
        "NDA Applicant Name": "Pierrel S.p.A.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "748",
        "Proprietary Name": "ORACEA",
        "Dosage Form": "Capsule",
        "Strength": "40mg",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "2/27/2023"
    },
    {
        "id": "749",
        "Proprietary Name": "ORACEA",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "04/2015"
    },
    {
        "id": "750",
        "Proprietary Name": "ORAPRED ODT",
        "Dosage Form": "Orally Disintegrating Tablets",
        "Strength": "30 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "751",
        "Proprietary Name": "ORAPRED ODT",
        "Dosage Form": "Orally Disintegrating Tablets",
        "Strength": "15 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "752",
        "Proprietary Name": "ORAPRED ODT",
        "Dosage Form": "Orally Disintegrating Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "10/2015"
    },
    {
        "id": "753",
        "Proprietary Name": "OSENI",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg/30 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "754",
        "Proprietary Name": "OSENI",
        "Dosage Form": "Tablets",
        "Strength": "25 mg/30 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "755",
        "Proprietary Name": "OSENI",
        "Dosage Form": "Tablets",
        "Strength": "25 mg/15 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "756",
        "Proprietary Name": "OSENI",
        "Dosage Form": "Tablets",
        "Strength": "25 mg/45 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "757",
        "Proprietary Name": "OTOVEL",
        "Dosage Form": "Otic Solution",
        "Strength": "0.3% / 0.025%",
        "NDA Applicant Name": "Laboratorios SALVAT, S.A.",
        "Date Authorized Generic Entered the Market": "11/2019"
    },
    {
        "id": "758",
        "Proprietary Name": "OVIDE",
        "Dosage Form": "Lotion",
        "Strength": "0.5%",
        "NDA Applicant Name": "Taro Pharmaceuticals USA, Inc.",
        "Date Authorized Generic Entered the Market": "08/02/2008 - 08/01/2009"
    },
    {
        "id": "759",
        "Proprietary Name": "OXANDRIN",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Savient Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2006 - 05/2007"
    },
    {
        "id": "760",
        "Proprietary Name": "OXANDRIN",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Savient Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2006 - 05/2007"
    },
    {
        "id": "761",
        "Proprietary Name": "OXYCODONE HYDROCHLORIDE",
        "Dosage Form": "Oral Solution",
        "Strength": "5 mg/5 mL",
        "NDA Applicant Name": "Genus Lifesciences, Inc.",
        "Date Authorized Generic Entered the Market": "09/2013"
    },
    {
        "id": "762",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "04/2022"
    },
    {
        "id": "763",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "03/24/2015"
    },
    {
        "id": "764",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "03/24/2015"
    },
    {
        "id": "765",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "03/24/2015"
    },
    {
        "id": "766",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "03/24/2015"
    },
    {
        "id": "767",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "04/2022"
    },
    {
        "id": "768",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "04/2022"
    },
    {
        "id": "769",
        "Proprietary Name": "OXYCONTIN",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "Purdue Pharma L.P.",
        "Date Authorized Generic Entered the Market": "04/2022"
    },
    {
        "id": "770",
        "Proprietary Name": "OZOBAX",
        "Dosage Form": "Solution",
        "Strength": "5mg/5mL",
        "NDA Applicant Name": "Metacel Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "03/15/2022"
    },
    {
        "id": "771",
        "Proprietary Name": "OZOBAX",
        "Dosage Form": "Solution",
        "Strength": "10mg/5mL",
        "NDA Applicant Name": "Metacel Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "10/12/2023"
    },
    {
        "id": "772",
        "Proprietary Name": "OZOBAX",
        "Dosage Form": "Solution",
        "Strength": "10mg/5mL",
        "NDA Applicant Name": "Metacel Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "03/05/2024"
    },
    {
        "id": "773",
        "Proprietary Name": "PARAPLATIN",
        "Dosage Form": "for Injection",
        "Strength": "50 mg/vial",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "03/2004 - 02/2005"
    },
    {
        "id": "774",
        "Proprietary Name": "PARAPLATIN",
        "Dosage Form": "for Injection",
        "Strength": "150 mg/vial",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "03/2004 - 02/2005"
    },
    {
        "id": "775",
        "Proprietary Name": "PARAPLATIN",
        "Dosage Form": "for Injection",
        "Strength": "450 mg/vial",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "03/2004 - 02/2005"
    },
    {
        "id": "776",
        "Proprietary Name": "PARAPLATIN AQ",
        "Dosage Form": "Injection",
        "Strength": "eq. 50 mg/5 mL (10 mg/mL)",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "07/2004 - 06/2005"
    },
    {
        "id": "777",
        "Proprietary Name": "PARAPLATIN AQ",
        "Dosage Form": "Injection",
        "Strength": "eq. 150 mg/15 mL (10 mg/mL)",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "07/2004 - 06/2005"
    },
    {
        "id": "778",
        "Proprietary Name": "PARAPLATIN AQ",
        "Dosage Form": "Injection",
        "Strength": "eq. 450 mg/45 mL (10 mg/mL)",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "07/2004 - 06/2005"
    },
    {
        "id": "779",
        "Proprietary Name": "PARAPLATIN AQ",
        "Dosage Form": "Injection",
        "Strength": "eq. 600 mg/60 mL (10 mg/mL)",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "07/2004 - 06/2005"
    },
    {
        "id": "780",
        "Proprietary Name": "PARNATE",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "02/05/2016"
    },
    {
        "id": "781",
        "Proprietary Name": "PATADAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.2%",
        "NDA Applicant Name": "Alcon Laboratories",
        "Date Authorized Generic Entered the Market": "06/2017"
    },
    {
        "id": "782",
        "Proprietary Name": "PATADAY",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.1%",
        "NDA Applicant Name": "Alcon Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "783",
        "Proprietary Name": "PATANOL",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "09/15/2015"
    },
    {
        "id": "784",
        "Proprietary Name": "PAXIL CR",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Apotex Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2019"
    },
    {
        "id": "785",
        "Proprietary Name": "PAXIL CR",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "37.5 mg",
        "NDA Applicant Name": "Apotex, Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2019"
    },
    {
        "id": "786",
        "Proprietary Name": "PAXIL CR",
        "Dosage Form": "Controlled- Release Tablets",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Apotex Inc.",
        "Date Authorized Generic Entered the Market": "08/09/2019"
    },
    {
        "id": "787",
        "Proprietary Name": "PEDIAPRED",
        "Dosage Form": "Oral Solution",
        "Strength": "5 mg / 5 mL",
        "NDA Applicant Name": "Seton Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "02/2002"
    },
    {
        "id": "788",
        "Proprietary Name": "PENNSAID",
        "Dosage Form": "Solution, Metered",
        "Strength": "2%",
        "NDA Applicant Name": "Horizon Therapeutics Ireland DAC",
        "Date Authorized Generic Entered the Market": "12/05/2022"
    },
    {
        "id": "789",
        "Proprietary Name": "PENNSAID",
        "Dosage Form": "Solution, Metered",
        "Strength": "2%",
        "NDA Applicant Name": "Horizon Therapeutics Ireland DAC",
        "Date Authorized Generic Entered the Market": "11/22/2022"
    },
    {
        "id": "790",
        "Proprietary Name": "PERFOROMIST",
        "Dosage Form": "Inhalation Solution",
        "Strength": "20 mcg/2 mL",
        "NDA Applicant Name": "Mylan Specialty L.P.",
        "Date Authorized Generic Entered the Market": "07/2021"
    },
    {
        "id": "791",
        "Proprietary Name": "PHOSLO",
        "Dosage Form": "Gelcaps",
        "Strength": "667 mg",
        "NDA Applicant Name": "Fresenius Medical Care North America",
        "Date Authorized Generic Entered the Market": "03/2014 - 03/2015"
    },
    {
        "id": "792",
        "Proprietary Name": "PLAN B ONE-STEP",
        "Dosage Form": "Tablets",
        "Strength": "1.5 mg",
        "NDA Applicant Name": "Foundation Consumer Healthcare, LLC",
        "Date Authorized Generic Entered the Market": "02/12/2014"
    },
    {
        "id": "793",
        "Proprietary Name": "PLAQUENIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "05/1999 - 04/2000"
    },
    {
        "id": "794",
        "Proprietary Name": "PLENDIL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "AstraZeneca LP",
        "Date Authorized Generic Entered the Market": "10/2008"
    },
    {
        "id": "795",
        "Proprietary Name": "PLENDIL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "AstraZeneca LP",
        "Date Authorized Generic Entered the Market": "10/2008"
    },
    {
        "id": "796",
        "Proprietary Name": "PLENDIL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "AstraZeneca LP",
        "Date Authorized Generic Entered the Market": "10/2008"
    },
    {
        "id": "797",
        "Proprietary Name": "PLIAGLIS",
        "Dosage Form": "Cream",
        "Strength": "7%/7%",
        "NDA Applicant Name": "Taro Pharmaceuticals USA, Inc.",
        "Date Authorized Generic Entered the Market": "11/2017"
    },
    {
        "id": "798",
        "Proprietary Name": "POLYTRIM",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "10 mL unit",
        "NDA Applicant Name": "Allergan, Inc.",
        "Date Authorized Generic Entered the Market": "04/29/1997"
    },
    {
        "id": "799",
        "Proprietary Name": "PONSTEL",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Shionogi, Inc.",
        "Date Authorized Generic Entered the Market": "07/11/2011"
    },
    {
        "id": "800",
        "Proprietary Name": "POTASSIUM CHLORIDE FOR ORAL SOLUTION",
        "Dosage Form": "Powder for Solution",
        "Strength": "20 mEq",
        "NDA Applicant Name": "Pharma Research Software Solution, LLC",
        "Date Authorized Generic Entered the Market": "09/2015"
    },
    {
        "id": "801",
        "Proprietary Name": "POTASSIUM CHLORIDE FOR ORAL SOLUTION",
        "Dosage Form": "Powder for Solution",
        "Strength": "20 mEq",
        "NDA Applicant Name": "Pharma Research Software Solution, LLC",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "802",
        "Proprietary Name": "POTASSIUM CHLORIDE ORAL SOLUTION, USP, 10%",
        "Dosage Form": "Oral Solution",
        "Strength": "20 mEq per 15 mL",
        "NDA Applicant Name": "Lehigh Valley Technologies",
        "Date Authorized Generic Entered the Market": "05/14/2015"
    },
    {
        "id": "803",
        "Proprietary Name": "POTASSIUM CHLORIDE ORAL SOLUTION, USP, 10%",
        "Dosage Form": "Oral Solution",
        "Strength": "20 mEq per 15 mL",
        "NDA Applicant Name": "Lehigh Valley Technologies",
        "Date Authorized Generic Entered the Market": "05/14/2015"
    },
    {
        "id": "804",
        "Proprietary Name": "POTASSIUM CHLORIDE ORAL SOLUTION, USP, 20%",
        "Dosage Form": "Oral Solution",
        "Strength": "40 mEq per 15 mL",
        "NDA Applicant Name": "Lehigh Valley Technologies",
        "Date Authorized Generic Entered the Market": "05/14/2015"
    },
    {
        "id": "805",
        "Proprietary Name": "PRAVACHOL",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "10/2005 - 09/2006"
    },
    {
        "id": "806",
        "Proprietary Name": "PRAVACHOL",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "10/2005 - 09/2006"
    },
    {
        "id": "807",
        "Proprietary Name": "PRAVACHOL",
        "Dosage Form": "Tablets",
        "Strength": "40 mg",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "10/2005 - 09/2006"
    },
    {
        "id": "808",
        "Proprietary Name": "PRAVACHOL",
        "Dosage Form": "Tablets",
        "Strength": "80 mg",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "10/2005 - 09/2006"
    },
    {
        "id": "809",
        "Proprietary Name": "PRED FORTE",
        "Dosage Form": "Ophthalmic Suspension",
        "Strength": "1%",
        "NDA Applicant Name": "Allergan, Inc.",
        "Date Authorized Generic Entered the Market": "08/1997"
    },
    {
        "id": "810",
        "Proprietary Name": "PREVACID",
        "Dosage Form": "Delayed- Release Capsules",
        "Strength": "15 mg",
        "NDA Applicant Name": "Takeda Global Research & Development Center, Inc.",
        "Date Authorized Generic Entered the Market": "11/2009"
    },
    {
        "id": "811",
        "Proprietary Name": "PREVACID",
        "Dosage Form": "Delayed- Release Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Takeda Global Research & Development Center, Inc.",
        "Date Authorized Generic Entered the Market": "11/2009"
    },
    {
        "id": "812",
        "Proprietary Name": "PREVPAC",
        "Dosage Form": "Delayed- Release Capsules, Capsules, and Tablets",
        "Strength": "30 mg, 500 mg, and 500 mg",
        "NDA Applicant Name": "Takeda Pharmaceuticals U.S.A., Inc.",
        "Date Authorized Generic Entered the Market": "03/02/2015"
    },
    {
        "id": "813",
        "Proprietary Name": "PRISTIQ",
        "Dosage Form": "Extended- Release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "03/2017"
    },
    {
        "id": "814",
        "Proprietary Name": "PRISTIQ",
        "Dosage Form": "Extended- Release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "03/2017"
    },
    {
        "id": "815",
        "Proprietary Name": "PRISTIQ",
        "Dosage Form": "Extended- Release Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "03/2017"
    },
    {
        "id": "816",
        "Proprietary Name": "PROAIR HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "90 mcg per acutation",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "01/2019"
    },
    {
        "id": "817",
        "Proprietary Name": "PROCARDIA",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "3/25/2013"
    },
    {
        "id": "818",
        "Proprietary Name": "PROLENSA",
        "Dosage Form": "Solution",
        "Strength": "0.07%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "1/8/2024"
    },
    {
        "id": "819",
        "Proprietary Name": "PROTOPIC",
        "Dosage Form": "Ointment",
        "Strength": "0.03%",
        "NDA Applicant Name": "LEO Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2014"
    },
    {
        "id": "820",
        "Proprietary Name": "PROTOPIC",
        "Dosage Form": "Ointment",
        "Strength": "0.1%",
        "NDA Applicant Name": "LEO Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2014"
    },
    {
        "id": "821",
        "Proprietary Name": "PROVENTIL HFA",
        "Dosage Form": "Inhalation Aerosol",
        "Strength": "108 mcg per actuation",
        "NDA Applicant Name": "Kindeva Drug Delivery L.P.",
        "Date Authorized Generic Entered the Market": "03/2021"
    },
    {
        "id": "822",
        "Proprietary Name": "PROVERA",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "6/18/2003"
    },
    {
        "id": "823",
        "Proprietary Name": "PROVERA",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "6/18/2003"
    },
    {
        "id": "824",
        "Proprietary Name": "PROVERA",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Pfizer",
        "Date Authorized Generic Entered the Market": "6/18/2003"
    },
    {
        "id": "825",
        "Proprietary Name": "PROVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Cephalon, Inc.",
        "Date Authorized Generic Entered the Market": "03/29/2012"
    },
    {
        "id": "826",
        "Proprietary Name": "PROVIGIL",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Cephalon Inc.",
        "Date Authorized Generic Entered the Market": "03/29/2012"
    },
    {
        "id": "827",
        "Proprietary Name": "QUALAQUIN",
        "Dosage Form": "Capsules",
        "Strength": "324 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "07/23/2012"
    },
    {
        "id": "828",
        "Proprietary Name": "QUARTETTE",
        "Dosage Form": "Tablets",
        "Strength": "0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg, and 0.01 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "829",
        "Proprietary Name": "QUDEXY XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "830",
        "Proprietary Name": "QUDEXY XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "831",
        "Proprietary Name": "QUDEXY XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "832",
        "Proprietary Name": "QUDEXY XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "25 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "833",
        "Proprietary Name": "QUDEXY XR",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "07/07/2014"
    },
    {
        "id": "834",
        "Proprietary Name": "RAPAMUNE",
        "Dosage Form": "Oral Solution",
        "Strength": "1 mg/mL",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "835",
        "Proprietary Name": "RAPAMUNE",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "01/16/2014"
    },
    {
        "id": "836",
        "Proprietary Name": "RAPAMUNE",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "10/27/2014"
    },
    {
        "id": "837",
        "Proprietary Name": "RAPAMUNE",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "10/27/2014"
    },
    {
        "id": "838",
        "Proprietary Name": "RAZADYNE",
        "Dosage Form": "Tablets",
        "Strength": "4 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "08/28/2008"
    },
    {
        "id": "839",
        "Proprietary Name": "RAZADYNE",
        "Dosage Form": "Tablets",
        "Strength": "8 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "08/28/2008"
    },
    {
        "id": "840",
        "Proprietary Name": "RAZADYNE ER",
        "Dosage Form": "Capsules",
        "Strength": "8 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "10/13/2008"
    },
    {
        "id": "841",
        "Proprietary Name": "RAZADYNE ER",
        "Dosage Form": "Capsules",
        "Strength": "16 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "10/13/2008"
    },
    {
        "id": "842",
        "Proprietary Name": "RAZADYNE ER",
        "Dosage Form": "Capsules",
        "Strength": "24 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "10/13/2008"
    },
    {
        "id": "843",
        "Proprietary Name": "REGLAN",
        "Dosage Form": "Injection",
        "Strength": "eq. 5 mg base/mL",
        "NDA Applicant Name": "Baxter Healthcare Corporation",
        "Date Authorized Generic Entered the Market": "02/2003 - 02/2004"
    },
    {
        "id": "844",
        "Proprietary Name": "REGLAN",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2021"
    },
    {
        "id": "845",
        "Proprietary Name": "REGLAN",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "12/2021"
    },
    {
        "id": "846",
        "Proprietary Name": "RENVELA",
        "Dosage Form": "Tablets",
        "Strength": "800 mg",
        "NDA Applicant Name": "Genzyme Corporation",
        "Date Authorized Generic Entered the Market": "04/16/2014"
    },
    {
        "id": "847",
        "Proprietary Name": "RESTORIL",
        "Dosage Form": "Capsule",
        "Strength": "30 mg",
        "NDA Applicant Name": "Mallinckrodt Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "08/02/2021"
    },
    {
        "id": "848",
        "Proprietary Name": "RESTORIL",
        "Dosage Form": "Capsule",
        "Strength": "15 mg",
        "NDA Applicant Name": "Mallinckrodt Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "04/20/2020"
    },
    {
        "id": "849",
        "Proprietary Name": "RESTORIL",
        "Dosage Form": "Capsules",
        "Strength": "22.5 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "07/21/2008"
    },
    {
        "id": "850",
        "Proprietary Name": "RESTORIL",
        "Dosage Form": "Capsules",
        "Strength": "7.5 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "07/22/2008"
    },
    {
        "id": "851",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2019"
    },
    {
        "id": "852",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Cream",
        "Strength": "0.025%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "853",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/2018"
    },
    {
        "id": "854",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/19/1974"
    },
    {
        "id": "855",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Cream",
        "Strength": "0.1 %",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "01/26/1973"
    },
    {
        "id": "856",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Gel",
        "Strength": "0.01 %",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "857",
        "Proprietary Name": "RETIN-A",
        "Dosage Form": "Gel",
        "Strength": "0.025%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "06/2005"
    },
    {
        "id": "858",
        "Proprietary Name": "RETIN-A MICRO",
        "Dosage Form": "Gel",
        "Strength": "0.1 %",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "859",
        "Proprietary Name": "RETIN-A MICRO",
        "Dosage Form": "Gel",
        "Strength": "0.1 %",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/2013"
    },
    {
        "id": "860",
        "Proprietary Name": "RETIN-A MICRO",
        "Dosage Form": "Gel",
        "Strength": "0.04 %",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "861",
        "Proprietary Name": "RETIN-A MICRO",
        "Dosage Form": "Gel",
        "Strength": "0.04%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "03/2013"
    },
    {
        "id": "862",
        "Proprietary Name": "REVATIO",
        "Dosage Form": "Powder for Suspension",
        "Strength": "10 mg/mL",
        "NDA Applicant Name": "Upjohn 1 US LLC",
        "Date Authorized Generic Entered the Market": "09/2019"
    },
    {
        "id": "863",
        "Proprietary Name": "REVATIO",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "09/27/2012, 11/09/2020"
    },
    {
        "id": "864",
        "Proprietary Name": "RISPERDAL",
        "Dosage Form": "Oral Solution",
        "Strength": "1 mg/mL",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "06/30/2008"
    },
    {
        "id": "865",
        "Proprietary Name": "RITALIN",
        "Dosage Form": "Tablet",
        "Strength": "5 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "866",
        "Proprietary Name": "RITALIN",
        "Dosage Form": "Tablet",
        "Strength": "20 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "867",
        "Proprietary Name": "RITALIN",
        "Dosage Form": "Tablet",
        "Strength": "10 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "868",
        "Proprietary Name": "RITALIN LA",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "11/2015"
    },
    {
        "id": "869",
        "Proprietary Name": "RITALIN LA",
        "Dosage Form": "Capsules",
        "Strength": "10 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "870",
        "Proprietary Name": "RITALIN LA",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "11/2015"
    },
    {
        "id": "871",
        "Proprietary Name": "RITALIN LA",
        "Dosage Form": "Capsules",
        "Strength": "30 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corp",
        "Date Authorized Generic Entered the Market": "11/2015"
    },
    {
        "id": "872",
        "Proprietary Name": "ROBINUL",
        "Dosage Form": "Injection",
        "Strength": "0.2 mg/mL",
        "NDA Applicant Name": "Eurohealth International Sarl",
        "Date Authorized Generic Entered the Market": "02/06/1975"
    },
    {
        "id": "873",
        "Proprietary Name": "ROBINUL",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "01/13/2005"
    },
    {
        "id": "874",
        "Proprietary Name": "ROBINUL FORTE",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "01/13/2005"
    },
    {
        "id": "875",
        "Proprietary Name": "ROCALTROL",
        "Dosage Form": "Oral Solution",
        "Strength": "1 mcg/mL (15 mL bottle)",
        "NDA Applicant Name": "Validus Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "08/26/2009"
    },
    {
        "id": "876",
        "Proprietary Name": "ROGAINE (FOR MEN)",
        "Dosage Form": "Topical Solution",
        "Strength": "2%",
        "NDA Applicant Name": "McNeil-PPC, Inc.",
        "Date Authorized Generic Entered the Market": "06/1998 - 05/1999"
    },
    {
        "id": "877",
        "Proprietary Name": "ROGAINE (FOR WOMEN)",
        "Dosage Form": "Topical Solution",
        "Strength": "2%",
        "NDA Applicant Name": "McNeil-PPC, Inc.",
        "Date Authorized Generic Entered the Market": "06/1998 - 05/1999"
    },
    {
        "id": "878",
        "Proprietary Name": "ROGAINE EXTRA STRENGTH (FOR MEN)",
        "Dosage Form": "Topical Solution",
        "Strength": "5%",
        "NDA Applicant Name": "McNeil-PPC, Inc.",
        "Date Authorized Generic Entered the Market": "2004"
    },
    {
        "id": "879",
        "Proprietary Name": "ROSZET",
        "Dosage Form": "Tablets",
        "Strength": "20 mg/10 mg",
        "NDA Applicant Name": "Althera Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "10/2021"
    },
    {
        "id": "880",
        "Proprietary Name": "ROSZET",
        "Dosage Form": "Tablets",
        "Strength": "10 mg/10 mg",
        "NDA Applicant Name": "Althera Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "10/2021"
    },
    {
        "id": "881",
        "Proprietary Name": "ROSZET",
        "Dosage Form": "Tablets",
        "Strength": "5 mg/10 mg",
        "NDA Applicant Name": "Althera Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "10/2021"
    },
    {
        "id": "882",
        "Proprietary Name": "ROSZET",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/10 mg",
        "NDA Applicant Name": "Althera Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "10/2021"
    },
    {
        "id": "883",
        "Proprietary Name": "ROWASA",
        "Dosage Form": "Rectal Suspension Enema",
        "Strength": "4 g/60 mL",
        "NDA Applicant Name": "Mylan Specialty, L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "2/2011"
    },
    {
        "id": "884",
        "Proprietary Name": "SAFRYAL",
        "Dosage Form": "Tablets",
        "Strength": "3 mg / 0.03 mg / 0.451 mg",
        "NDA Applicant Name": "Bayer HealthCare LLC",
        "Date Authorized Generic Entered the Market": "08/2015"
    },
    {
        "id": "885",
        "Proprietary Name": "SALAGEN",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "12/2004"
    },
    {
        "id": "886",
        "Proprietary Name": "SALAGEN",
        "Dosage Form": "Tablets",
        "Strength": "7.5 mg",
        "NDA Applicant Name": "Concordia Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "03/2006 - 01/2007"
    },
    {
        "id": "887",
        "Proprietary Name": "SAMSCA",
        "Dosage Form": "Tablets",
        "Strength": "15 mg",
        "NDA Applicant Name": "Otsuka Pharmaceutical Company, Ltd.",
        "Date Authorized Generic Entered the Market": "10/2020"
    },
    {
        "id": "888",
        "Proprietary Name": "SAPHRIS SAPHRIS",
        "Dosage Form": "Sublingual Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "05/2020"
    },
    {
        "id": "889",
        "Proprietary Name": "SAPHRIS SAPHRIS",
        "Dosage Form": "Sublingual Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "05/2020"
    },
    {
        "id": "890",
        "Proprietary Name": "SAPHRIS SAPHRIS",
        "Dosage Form": "Sublingual Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "12/2020"
    },
    {
        "id": "891",
        "Proprietary Name": "SEASONALE",
        "Dosage Form": "Tablets",
        "Strength": "0.15 mg/0.03 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "9/7/2006"
    },
    {
        "id": "892",
        "Proprietary Name": "SEASONIQUE",
        "Dosage Form": "Tablets",
        "Strength": "0.15 mg/0.03 mg and 0.01 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "07/28/2010"
    },
    {
        "id": "893",
        "Proprietary Name": "SECTRAL",
        "Dosage Form": "Capsules",
        "Strength": "eq. 200 mg base",
        "NDA Applicant Name": "Wyeth Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "894",
        "Proprietary Name": "SECTRAL",
        "Dosage Form": "Capsules",
        "Strength": "eq. 400 mg base",
        "NDA Applicant Name": "Wyeth Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "895",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:200,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2015"
    },
    {
        "id": "896",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:200,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "04/2016"
    },
    {
        "id": "897",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "898",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2015"
    },
    {
        "id": "899",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2015"
    },
    {
        "id": "900",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2016"
    },
    {
        "id": "901",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:200,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "04/2019"
    },
    {
        "id": "902",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:200,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2015"
    },
    {
        "id": "903",
        "Proprietary Name": "SEPTOCAINE",
        "Dosage Form": "Injection",
        "Strength": "4% and 1:100,000",
        "NDA Applicant Name": "Deproco, Inc.",
        "Date Authorized Generic Entered the Market": "01/2015"
    },
    {
        "id": "904",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tables",
        "Strength": "200 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "905",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "906",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "907",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "908",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "909",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "910",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "911",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "05/2017"
    },
    {
        "id": "912",
        "Proprietary Name": "SEROQUEL XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "AstraZeneca UK Limited",
        "Date Authorized Generic Entered the Market": "11/2016"
    },
    {
        "id": "913",
        "Proprietary Name": "SILENOR",
        "Dosage Form": "Tablets",
        "Strength": "6 mg",
        "NDA Applicant Name": "Currax Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "08/2010"
    },
    {
        "id": "914",
        "Proprietary Name": "SILENOR",
        "Dosage Form": "Tablets",
        "Strength": "3 mg",
        "NDA Applicant Name": "Currax Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "08/2010"
    },
    {
        "id": "915",
        "Proprietary Name": "SILVADENE",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "King Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "916",
        "Proprietary Name": "SKELAXIN",
        "Dosage Form": "Tablets",
        "Strength": "800 mg",
        "NDA Applicant Name": "King Pharmaceuticals R&D, LLC",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "917",
        "Proprietary Name": "SOLARAZE",
        "Dosage Form": "Gel",
        "Strength": "3%",
        "NDA Applicant Name": "Fougera Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "11/21/2013"
    },
    {
        "id": "918",
        "Proprietary Name": "SOMA",
        "Dosage Form": "Tablet",
        "Strength": "250 mg",
        "NDA Applicant Name": "Mylan Specialty, L.P.",
        "Date Authorized Generic Entered the Market": "9/13/2010"
    },
    {
        "id": "919",
        "Proprietary Name": "SOOLANTRA",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "06/2021"
    },
    {
        "id": "920",
        "Proprietary Name": "SOOLANTRA",
        "Dosage Form": "Cream",
        "Strength": "1%",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "1/8/2024"
    },
    {
        "id": "921",
        "Proprietary Name": "SORILUX",
        "Dosage Form": "Foam",
        "Strength": "0.005%",
        "NDA Applicant Name": "Mayne Pharma LLC",
        "Date Authorized Generic Entered the Market": "02/2021"
    },
    {
        "id": "922",
        "Proprietary Name": "SPECTRACEF",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Vansen Pharma, Inc.",
        "Date Authorized Generic Entered the Market": "Unknown"
    },
    {
        "id": "923",
        "Proprietary Name": "SPECTRACEF",
        "Dosage Form": "Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "Vansen Pharma, Inc.",
        "Date Authorized Generic Entered the Market": "Unknown"
    },
    {
        "id": "924",
        "Proprietary Name": "SPORANOX",
        "Dosage Form": "Capsule",
        "Strength": "100 mg",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "2/2005; 6/2005"
    },
    {
        "id": "925",
        "Proprietary Name": "SPORANOX",
        "Dosage Form": "Oral Solution",
        "Strength": "10 mg/mL",
        "NDA Applicant Name": "Janssen Research & Development, LLC",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "926",
        "Proprietary Name": "STALEVO 100",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "25 mg, 100 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "927",
        "Proprietary Name": "STALEVO 125",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "31.25 mg, 125 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "928",
        "Proprietary Name": "STALEVO 150",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "37.5 mg, 150 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "929",
        "Proprietary Name": "STALEVO 200",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "50 mg, 200 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "930",
        "Proprietary Name": "STALEVO 50",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "12.5 mg, 50 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "931",
        "Proprietary Name": "STALEVO 75",
        "Dosage Form": "Film-coated Tablets",
        "Strength": "18.75 mg, 75 mg, 200 mg",
        "NDA Applicant Name": "Orion Corporation",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "932",
        "Proprietary Name": "SULAR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "17 mg",
        "NDA Applicant Name": "Covis Pharma GmbH/Cardinal Health Regulatory",
        "Date Authorized Generic Entered the Market": "2/2012 - 2/2013"
    },
    {
        "id": "933",
        "Proprietary Name": "SULAR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "34 mg",
        "NDA Applicant Name": "Covis Pharma GmbH/Cardinal Health Regulatory",
        "Date Authorized Generic Entered the Market": "2/2012 - 2/2013"
    },
    {
        "id": "934",
        "Proprietary Name": "SULAR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "8.5 mg",
        "NDA Applicant Name": "Covis Pharma GmbH/Cardinal Health Regulatory",
        "Date Authorized Generic Entered the Market": "2/2012 - 2/2013"
    },
    {
        "id": "935",
        "Proprietary Name": "SUPRAX",
        "Dosage Form": "Capsules",
        "Strength": "400 mg",
        "NDA Applicant Name": "Lupin Limited",
        "Date Authorized Generic Entered the Market": "10/2020"
    },
    {
        "id": "936",
        "Proprietary Name": "SUPREP",
        "Dosage Form": "Oral Solution (concentrate)",
        "Strength": "17.5g / 3.13g / 1.6g",
        "NDA Applicant Name": "Braintree Laboratories, Inc.",
        "Date Authorized Generic Entered the Market": "08/2010"
    },
    {
        "id": "937",
        "Proprietary Name": "SYMBICORT",
        "Dosage Form": "Metered Dose Inhaler",
        "Strength": "160/4.5 mcg",
        "NDA Applicant Name": "AstraZeneca Pharmaceuticals LP",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "938",
        "Proprietary Name": "SYMBICORT",
        "Dosage Form": "Metered Dose Inhaler",
        "Strength": "80/4.5 mcg",
        "NDA Applicant Name": "AstraZeneca Pharmaceuticals LP",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "939",
        "Proprietary Name": "SYNALAR",
        "Dosage Form": "Cream",
        "Strength": ".25 mg/g",
        "NDA Applicant Name": "Medimetriks Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "5/7/2024"
    },
    {
        "id": "940",
        "Proprietary Name": "SYNALAR",
        "Dosage Form": "Cream",
        "Strength": ".1 mg/g",
        "NDA Applicant Name": "Medimetriks Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "5/7/2024"
    },
    {
        "id": "941",
        "Proprietary Name": "SYNALAR",
        "Dosage Form": "Ointment",
        "Strength": "0.025%",
        "NDA Applicant Name": "Medimetriks Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "11/2023"
    },
    {
        "id": "942",
        "Proprietary Name": "SYNALGOS-DC",
        "Dosage Form": "Capsules",
        "Strength": "356.4 mg/30 mg/16 mg",
        "NDA Applicant Name": "Sun Pharmaceutical Industries, Inc.",
        "Date Authorized Generic Entered the Market": "10/01/2012"
    },
    {
        "id": "943",
        "Proprietary Name": "SYPRINE",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Bausch Health Americas, Inc.",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "944",
        "Proprietary Name": "TACLONEX",
        "Dosage Form": "Ointment",
        "Strength": "0.005%/0.064%",
        "NDA Applicant Name": "LEO Pharma A/S",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "945",
        "Proprietary Name": "TAMBOCOR",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "3M Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "10/2002"
    },
    {
        "id": "946",
        "Proprietary Name": "TAMBOCOR",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "3M Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "10/2002"
    },
    {
        "id": "947",
        "Proprietary Name": "TAMBOCOR",
        "Dosage Form": "Tablets",
        "Strength": "150 mg",
        "NDA Applicant Name": "3M Pharmaceuticals",
        "Date Authorized Generic Entered the Market": "10/2002"
    },
    {
        "id": "948",
        "Proprietary Name": "TARGRETIN",
        "Dosage Form": "Gel",
        "Strength": "1%",
        "NDA Applicant Name": "Bausch Health Ireland Limited",
        "Date Authorized Generic Entered the Market": "06/2022"
    },
    {
        "id": "949",
        "Proprietary Name": "TASMAR",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2004"
    },
    {
        "id": "950",
        "Proprietary Name": "TAXOTERE",
        "Dosage Form": "Injection Concentrate",
        "Strength": "80 mg/4 mL (20 mg/mL)",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "03/2011"
    },
    {
        "id": "951",
        "Proprietary Name": "TAXOTERE",
        "Dosage Form": "Injection Concentrate",
        "Strength": "20 mg/mL",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "03/2011"
    },
    {
        "id": "952",
        "Proprietary Name": "TAXOTERE",
        "Dosage Form": "Injection Concentrate",
        "Strength": "160 mg/8 mL (20 mg/mL)",
        "NDA Applicant Name": "Sanofi Aventis US LLC",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "953",
        "Proprietary Name": "TAYTULLA",
        "Dosage Form": "Capsules",
        "Strength": "1 mg/20 mcg",
        "NDA Applicant Name": "Allergan Pharmaceuticals International Ltd",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "954",
        "Proprietary Name": "TAZORAC",
        "Dosage Form": "Cream",
        "Strength": "0.1%",
        "NDA Applicant Name": "Allergan Aesthetics, an Abbvie Company",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "955",
        "Proprietary Name": "TAZORAC",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Allergan Aesthetics, an Abbvie Company",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "956",
        "Proprietary Name": "TEGRETOL XR",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "07/2018"
    },
    {
        "id": "957",
        "Proprietary Name": "TEGRETOL XR",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "06/15/2009"
    },
    {
        "id": "958",
        "Proprietary Name": "TEGRETOL XR",
        "Dosage Form": "Tablets",
        "Strength": "400 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "06/15/2009"
    },
    {
        "id": "959",
        "Proprietary Name": "TESTIM",
        "Dosage Form": "Gel",
        "Strength": "50 mg in 5 g",
        "NDA Applicant Name": "Auxilium Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/09/2014"
    },
    {
        "id": "960",
        "Proprietary Name": "TETRACAINE HYDROCHLORIDE",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch Health Ireland Limited",
        "Date Authorized Generic Entered the Market": "06/2019"
    },
    {
        "id": "961",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "240 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "962",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "120 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "963",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "180 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "964",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "420 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "965",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Bausch Health US, LLC Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "966",
        "Proprietary Name": "TIAZAC",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "360 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/20/2014"
    },
    {
        "id": "967",
        "Proprietary Name": "TIGAN",
        "Dosage Form": "Injection",
        "Strength": "100 mg/mL",
        "NDA Applicant Name": "Par Sterile Products, LLC",
        "Date Authorized Generic Entered the Market": "06/01/2012"
    },
    {
        "id": "968",
        "Proprietary Name": "TIMOPTIC",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "969",
        "Proprietary Name": "TIMOPTIC",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "06/2020"
    },
    {
        "id": "970",
        "Proprietary Name": "TIMOPTIC in OCUDOSE",
        "Dosage Form": "Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "04/2021"
    },
    {
        "id": "971",
        "Proprietary Name": "TIMOPTIC-XE",
        "Dosage Form": "Solution",
        "Strength": "0.25%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "972",
        "Proprietary Name": "TIMOPTIC-XE",
        "Dosage Form": "Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Bausch & Lomb Incorporated",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "973",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "25 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "974",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "13 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "975",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "50 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "976",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "75 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "977",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "88 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "978",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "100 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "979",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "200 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "980",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "125 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "981",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "137 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "982",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "175 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "983",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "175 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "984",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "150 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "985",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "112 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "03/01/2023"
    },
    {
        "id": "986",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "75 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "987",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "200 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "988",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "150 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "989",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "137 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "990",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "125 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "991",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "112 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "992",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "100 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "993",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "88 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "994",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "50 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "995",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "25 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "996",
        "Proprietary Name": "TIROSINT",
        "Dosage Form": "Capsules",
        "Strength": "13 mcg",
        "NDA Applicant Name": "IBSA Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/2020"
    },
    {
        "id": "997",
        "Proprietary Name": "TIVORBEX",
        "Dosage Form": "Capsules",
        "Strength": "20 mg",
        "NDA Applicant Name": "Genus Lifesciences Inc.",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "998",
        "Proprietary Name": "TIVORBEX",
        "Dosage Form": "Capsules",
        "Strength": "40 mg",
        "NDA Applicant Name": "Genus Lifesciences Inc.",
        "Date Authorized Generic Entered the Market": "01/2020"
    },
    {
        "id": "999",
        "Proprietary Name": "TOBI",
        "Dosage Form": "Solution for Inhalation",
        "Strength": "300 mg/5 mL ampule",
        "NDA Applicant Name": "Mylan Specialty, L.P., a Viatris Company",
        "Date Authorized Generic Entered the Market": "07/2014"
    },
    {
        "id": "1000",
        "Proprietary Name": "TOBRADEX",
        "Dosage Form": "Opthalmic Suspension",
        "Strength": "0.3% and 0.1%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/02/2009"
    },
    {
        "id": "1001",
        "Proprietary Name": "TOFRONIL PM",
        "Dosage Form": "Capsules",
        "Strength": "75 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "4/2006"
    },
    {
        "id": "1002",
        "Proprietary Name": "TOFRONIL PM",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "4/2006"
    },
    {
        "id": "1003",
        "Proprietary Name": "TOFRONIL PM",
        "Dosage Form": "Capsules",
        "Strength": "125 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "4/2006"
    },
    {
        "id": "1004",
        "Proprietary Name": "TOFRONIL PM",
        "Dosage Form": "Capsules",
        "Strength": "150 mg",
        "NDA Applicant Name": "Mallinckrodt Inc.",
        "Date Authorized Generic Entered the Market": "4/2006"
    },
    {
        "id": "1005",
        "Proprietary Name": "TOPROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Toprol Acquisition LLC",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "1006",
        "Proprietary Name": "TOPROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Toprol Acquisition LLC",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "1007",
        "Proprietary Name": "TOPROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Toprol Acquisition LLC",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "1008",
        "Proprietary Name": "TOPROL XL",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Toprol Acquisition LLC",
        "Date Authorized Generic Entered the Market": "01/2018"
    },
    {
        "id": "1009",
        "Proprietary Name": "TRANDATE",
        "Dosage Form": "Tablets",
        "Strength": "300 mg",
        "NDA Applicant Name": "Alvogen, Inc.",
        "Date Authorized Generic Entered the Market": "03/2018"
    },
    {
        "id": "1010",
        "Proprietary Name": "TRANDATE",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Alvogen, Inc.",
        "Date Authorized Generic Entered the Market": "12/01/2014"
    },
    {
        "id": "1011",
        "Proprietary Name": "TRANDATE",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Alvogen, Inc.",
        "Date Authorized Generic Entered the Market": "03/2018"
    },
    {
        "id": "1012",
        "Proprietary Name": "TRAVATAN Z",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.004%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "12/2019"
    },
    {
        "id": "1013",
        "Proprietary Name": "TREXIMET",
        "Dosage Form": "Tablets",
        "Strength": "85 mg/500 mg",
        "NDA Applicant Name": "Currax Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "02/2018"
    },
    {
        "id": "1014",
        "Proprietary Name": "TRIBENZOR",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/5 mg/12.5 mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1015",
        "Proprietary Name": "TRIBENZOR",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/10 mg/12.5 mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1016",
        "Proprietary Name": "TRIBENZOR",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/10 mg/25 mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1017",
        "Proprietary Name": "TRIBENZOR",
        "Dosage Form": "Tablets",
        "Strength": "40 mg/5 mg/25 mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1018",
        "Proprietary Name": "TRIBENZOR",
        "Dosage Form": "Tablets",
        "Strength": "20 mg/5 mg/12.5 mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1019",
        "Proprietary Name": "TRILEPTAL",
        "Dosage Form": "Oral Suspension",
        "Strength": "300 mg/5 mL",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "12/2009"
    },
    {
        "id": "1020",
        "Proprietary Name": "TRILIPIX",
        "Dosage Form": "Delayed Release Capsules",
        "Strength": "135 mg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "07/15/2013"
    },
    {
        "id": "1021",
        "Proprietary Name": "TRI-NORINYL",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg and 0.035 mg, 1 mg and 0.035 mg",
        "NDA Applicant Name": "Mayne Pharma LLC",
        "Date Authorized Generic Entered the Market": "1/12/2005"
    },
    {
        "id": "1022",
        "Proprietary Name": "TUSSIONEX",
        "Dosage Form": "Extended- Release Suspension",
        "Strength": "10 mg hydrocodone bitartrate & 8 mg chlorpheniramine maleate per 5 mL",
        "NDA Applicant Name": "UCB, Inc.",
        "Date Authorized Generic Entered the Market": "10/2010"
    },
    {
        "id": "1023",
        "Proprietary Name": "UCERIS",
        "Dosage Form": "Extended- Release Tablets",
        "Strength": "9 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "07/2018"
    },
    {
        "id": "1024",
        "Proprietary Name": "ULTRAVATE",
        "Dosage Form": "Cream",
        "Strength": "0.05%",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "11/2004 - 10/2005"
    },
    {
        "id": "1025",
        "Proprietary Name": "ULTRAVATE",
        "Dosage Form": "Ointment",
        "Strength": "0.05%",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "11/2004 - 10/2005"
    },
    {
        "id": "1026",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "137 mcg (0.137 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "unknown"
    },
    {
        "id": "1027",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "25 mcg (0.025 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1028",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "50 mcg (0.05 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1029",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "75 mcg (0.075 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1030",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "88 mcg (0.088 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1031",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "100 mcg (0.1 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1032",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "112 mcg (0.112 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1033",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "125 mcg (0.125 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1034",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "150 mcg (0.15 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1035",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "175 mcg (0.175 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1036",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "200 mcg (0.2 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1037",
        "Proprietary Name": "UNITHROID",
        "Dosage Form": "Tablets",
        "Strength": "300 mcg (0.3 mg)",
        "NDA Applicant Name": "Jerome Stevens Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2002 - 07/2003"
    },
    {
        "id": "1038",
        "Proprietary Name": "UREX",
        "Dosage Form": "Tablets",
        "Strength": "1 gram",
        "NDA Applicant Name": "County Line Pharmaceuticals, LLC",
        "Date Authorized Generic Entered the Market": "05/2010"
    },
    {
        "id": "1039",
        "Proprietary Name": "UROCIT-K",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "540 mg (5 mEq per tablet)",
        "NDA Applicant Name": "Mission Pharmacal Company",
        "Date Authorized Generic Entered the Market": "11/2007"
    },
    {
        "id": "1040",
        "Proprietary Name": "UROCIT-K",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "15 mEq (1620 mg) per tablet",
        "NDA Applicant Name": "Mission Pharmacal Company",
        "Date Authorized Generic Entered the Market": "12/23/2013"
    },
    {
        "id": "1041",
        "Proprietary Name": "URSO 250",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "07/06/2009"
    },
    {
        "id": "1042",
        "Proprietary Name": "URSO FORTE",
        "Dosage Form": "Tablets",
        "Strength": "500 mg",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "07/06/2009"
    },
    {
        "id": "1043",
        "Proprietary Name": "VAGISTAT-1",
        "Dosage Form": "Vaginal Ointment",
        "Strength": "6.50%",
        "NDA Applicant Name": "Bristol-Myers Squibb Company",
        "Date Authorized Generic Entered the Market": "02/1998 - 02/1999"
    },
    {
        "id": "1044",
        "Proprietary Name": "VANCOCIN",
        "Dosage Form": "Capsules",
        "Strength": "125 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "10/26/2015"
    },
    {
        "id": "1045",
        "Proprietary Name": "VANCOCIN",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "ANI Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "10/26/2015"
    },
    {
        "id": "1046",
        "Proprietary Name": "VASERETIC",
        "Dosage Form": "Tablets",
        "Strength": "10 mg/25 mg",
        "NDA Applicant Name": "Valeant Pharmaceuticals North America, LLC",
        "Date Authorized Generic Entered the Market": "10/31/1986"
    },
    {
        "id": "1047",
        "Proprietary Name": "VASOTEC",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/26/1988"
    },
    {
        "id": "1048",
        "Proprietary Name": "VASOTEC",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/24/1985"
    },
    {
        "id": "1049",
        "Proprietary Name": "VASOTEC",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/24/1985"
    },
    {
        "id": "1050",
        "Proprietary Name": "VASOTEC",
        "Dosage Form": "Tablets",
        "Strength": "20 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "12/24/1985"
    },
    {
        "id": "1051",
        "Proprietary Name": "VECTICAL",
        "Dosage Form": "Ointment",
        "Strength": "3 mcg/g",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "7/21/2023"
    },
    {
        "id": "1052",
        "Proprietary Name": "VECTICAL",
        "Dosage Form": "Ointment",
        "Strength": "3 mcg/g",
        "NDA Applicant Name": "Galderma Laboratories, L.P.",
        "Date Authorized Generic Entered the Market": "02/28/2012"
    },
    {
        "id": "1053",
        "Proprietary Name": "VELTIN",
        "Dosage Form": "Gel",
        "Strength": "1.2%/0.025%",
        "NDA Applicant Name": "Almirall, LLC",
        "Date Authorized Generic Entered the Market": "06/2018"
    },
    {
        "id": "1054",
        "Proprietary Name": "VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS",
        "Dosage Form": "Tablet, Extended Release",
        "Strength": "37.5 mg",
        "NDA Applicant Name": "Osmotica Pharmaceutical US LLC",
        "Date Authorized Generic Entered the Market": "04/2010"
    },
    {
        "id": "1055",
        "Proprietary Name": "VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS",
        "Dosage Form": "Tablet, Extended Release",
        "Strength": "225 mg",
        "NDA Applicant Name": "Osmotica Pharmaceutical US LLC",
        "Date Authorized Generic Entered the Market": "04/2010"
    },
    {
        "id": "1056",
        "Proprietary Name": "VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS",
        "Dosage Form": "Tablet, Extended Release",
        "Strength": "75 mg",
        "NDA Applicant Name": "Osmotica Pharmaceutical US LLC",
        "Date Authorized Generic Entered the Market": "04/2010"
    },
    {
        "id": "1057",
        "Proprietary Name": "VENLAFAXINE HYDROCHLORIDE EXTENDED RELEASE TABLETS",
        "Dosage Form": "Tablet, Extended Release",
        "Strength": "150 mg",
        "NDA Applicant Name": "Osmotica Pharmaceutical US LLC",
        "Date Authorized Generic Entered the Market": "04/2010"
    },
    {
        "id": "1058",
        "Proprietary Name": "VENOFER",
        "Dosage Form": "Injection",
        "Strength": "2% w/v iron (Fe)",
        "NDA Applicant Name": "Luitpold Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "10/02/08"
    },
    {
        "id": "1059",
        "Proprietary Name": "VENTOLIN HFA",
        "Dosage Form": "Metered-dose Inhaler",
        "Strength": "90 mcg per actuation",
        "NDA Applicant Name": "GlaxoSmithKline Intellectual Property Mgmt Ltd",
        "Date Authorized Generic Entered the Market": "01/2019"
    },
    {
        "id": "1060",
        "Proprietary Name": "VERELAN",
        "Dosage Form": "Sustained- release Capsules",
        "Strength": "120 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "5/17/1999"
    },
    {
        "id": "1061",
        "Proprietary Name": "VERELAN",
        "Dosage Form": "Sustained- release Capsules",
        "Strength": "180 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "5/17/1999"
    },
    {
        "id": "1062",
        "Proprietary Name": "VERELAN",
        "Dosage Form": "Sustained- release Capsules",
        "Strength": "240 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "5/17/1999"
    },
    {
        "id": "1063",
        "Proprietary Name": "VERELAN",
        "Dosage Form": "Sustained- release Capsules",
        "Strength": "360 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "5/17/1999"
    },
    {
        "id": "1064",
        "Proprietary Name": "VERELAN PM",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "11/2006 - 11/2007"
    },
    {
        "id": "1065",
        "Proprietary Name": "VERELAN PM",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "200 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "11/2006 - 11/2007"
    },
    {
        "id": "1066",
        "Proprietary Name": "VERELAN PM",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "300 mg",
        "NDA Applicant Name": "Societal CDMO Gainesville, LLC",
        "Date Authorized Generic Entered the Market": "11/2006 - 11/2007"
    },
    {
        "id": "1067",
        "Proprietary Name": "VFEND",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "40 mg/mL (75 mL when reconstituted)",
        "NDA Applicant Name": "PF Prism C.V.",
        "Date Authorized Generic Entered the Market": "12/16/2013"
    },
    {
        "id": "1068",
        "Proprietary Name": "VIAGRA",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/1/2017"
    },
    {
        "id": "1069",
        "Proprietary Name": "VIAGRA",
        "Dosage Form": "Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "1070",
        "Proprietary Name": "VIAGRA",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "12/2017"
    },
    {
        "id": "1071",
        "Proprietary Name": "VIBRAMYCIN",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "05/2015"
    },
    {
        "id": "1072",
        "Proprietary Name": "VIGAMOX",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5%",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "01/2017"
    },
    {
        "id": "1073",
        "Proprietary Name": "VIMOVO",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "375 mg /20 mg",
        "NDA Applicant Name": "Horizon Medicines, LLC",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "1074",
        "Proprietary Name": "VIMOVO",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "500 mg/20 mg",
        "NDA Applicant Name": "Horizon Medicines, LLC",
        "Date Authorized Generic Entered the Market": "03/2020"
    },
    {
        "id": "1075",
        "Proprietary Name": "VIRAZOLE",
        "Dosage Form": "Inhalation Solution, USP",
        "Strength": "100 mL/6G Vial",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "4/15/2020"
    },
    {
        "id": "1076",
        "Proprietary Name": "VIRAZOLE",
        "Dosage Form": "Powder for Solution",
        "Strength": "6g/100 mL vial, to be reconstituted",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "04/2017"
    },
    {
        "id": "1077",
        "Proprietary Name": "VISTARIL",
        "Dosage Form": "Capsules",
        "Strength": "50 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "07/2020"
    },
    {
        "id": "1078",
        "Proprietary Name": "VIVELLE-DOT",
        "Dosage Form": "Transdermal System",
        "Strength": "0.1 mg",
        "NDA Applicant Name": "Sandoz Inc",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "1079",
        "Proprietary Name": "VIVELLE-DOT",
        "Dosage Form": "Transdermal System",
        "Strength": "0.0375 mg",
        "NDA Applicant Name": "Sandoz, Inc",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "1080",
        "Proprietary Name": "VIVELLE-DOT",
        "Dosage Form": "Transdermal System",
        "Strength": "0.05 mg",
        "NDA Applicant Name": "Sandoz Inc",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "1081",
        "Proprietary Name": "VIVELLE-DOT",
        "Dosage Form": "Transdermal System",
        "Strength": "0.075 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "1082",
        "Proprietary Name": "VIVELLE-DOT",
        "Dosage Form": "Transdermal System",
        "Strength": "0.025 mg",
        "NDA Applicant Name": "Sandoz Inc",
        "Date Authorized Generic Entered the Market": "12/2014"
    },
    {
        "id": "1083",
        "Proprietary Name": "VOGELXO",
        "Dosage Form": "Gel",
        "Strength": "50 mg",
        "NDA Applicant Name": "Upsher-Smith Laboratories, LLC",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "1084",
        "Proprietary Name": "VOLTAREN",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "1085",
        "Proprietary Name": "VOLTAREN",
        "Dosage Form": "Delayed-release Tablets",
        "Strength": "50 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "Prior to 1/1/1999"
    },
    {
        "id": "1086",
        "Proprietary Name": "VOLTAREN",
        "Dosage Form": "Gel",
        "Strength": "1%",
        "NDA Applicant Name": "GlaxoSmithKline Consumer Healthcare",
        "Date Authorized Generic Entered the Market": "07/2016"
    },
    {
        "id": "1087",
        "Proprietary Name": "VOLTAREN XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Novartis Pharmaceuticals Corporation",
        "Date Authorized Generic Entered the Market": "05/22/2000"
    },
    {
        "id": "1088",
        "Proprietary Name": "VUSION",
        "Dosage Form": "Ointment",
        "Strength": "0.25%, 15%, and 81.35%",
        "NDA Applicant Name": "Mylan Pharmaceuticals Inc., a Viatris Company",
        "Date Authorized Generic Entered the Market": "11/2018"
    },
    {
        "id": "1089",
        "Proprietary Name": "WELCHOL",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "3.75 g packet",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2022"
    },
    {
        "id": "1090",
        "Proprietary Name": "WELCHOL",
        "Dosage Form": "Tablets",
        "Strength": "625mg",
        "NDA Applicant Name": "Cosette Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "8/1/2022"
    },
    {
        "id": "1091",
        "Proprietary Name": "XALATAN",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.005% (125 mcg/2.5 mL)",
        "NDA Applicant Name": "Upjohn US 2, LLC",
        "Date Authorized Generic Entered the Market": "11/15/2010"
    },
    {
        "id": "1092",
        "Proprietary Name": "XANAX",
        "Dosage Form": "Tablets",
        "Strength": "0.25 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "06/17/2003"
    },
    {
        "id": "1093",
        "Proprietary Name": "XANAX",
        "Dosage Form": "Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "1094",
        "Proprietary Name": "XANAX",
        "Dosage Form": "Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "1095",
        "Proprietary Name": "XANAX",
        "Dosage Form": "Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "06/18/2003"
    },
    {
        "id": "1096",
        "Proprietary Name": "XANAX XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "0.5 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "11/16/2005"
    },
    {
        "id": "1097",
        "Proprietary Name": "XANAX XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "1 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "11/16/2005"
    },
    {
        "id": "1098",
        "Proprietary Name": "XANAX XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "2 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "11/16/2005"
    },
    {
        "id": "1099",
        "Proprietary Name": "XANAX XR",
        "Dosage Form": "Extended- release Tablets",
        "Strength": "3 mg",
        "NDA Applicant Name": "Upjohn US 2 LLC",
        "Date Authorized Generic Entered the Market": "11/16/2005"
    },
    {
        "id": "1100",
        "Proprietary Name": "XENAZINE",
        "Dosage Form": "Tablets",
        "Strength": "25 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/20/2015"
    },
    {
        "id": "1101",
        "Proprietary Name": "XENAZINE",
        "Dosage Form": "Tablets",
        "Strength": "12.5 mg",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/20/2015"
    },
    {
        "id": "1102",
        "Proprietary Name": "XENICAL",
        "Dosage Form": "Capsules",
        "Strength": "120 mg",
        "NDA Applicant Name": "CHEPLAPHARM Arzneimittel GmbH",
        "Date Authorized Generic Entered the Market": "6/1/2022"
    },
    {
        "id": "1103",
        "Proprietary Name": "XIMINO",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "45 mg",
        "NDA Applicant Name": "Journey Medical Corporation",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "1104",
        "Proprietary Name": "XIMINO",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "135 mg",
        "NDA Applicant Name": "Journey Medical Corporation",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "1105",
        "Proprietary Name": "XIMINO",
        "Dosage Form": "Extended- release Capsules",
        "Strength": "90 mg",
        "NDA Applicant Name": "Journey Medical Corporation",
        "Date Authorized Generic Entered the Market": "04/2020"
    },
    {
        "id": "1106",
        "Proprietary Name": "XOPENEX",
        "Dosage Form": "Inhalation Solution",
        "Strength": "0.63 mg/3 mL",
        "NDA Applicant Name": "Oak Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2012"
    },
    {
        "id": "1107",
        "Proprietary Name": "XOPENEX",
        "Dosage Form": "Inhalation Solution",
        "Strength": "0.31 mg/3 mL",
        "NDA Applicant Name": "Oak Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2012"
    },
    {
        "id": "1108",
        "Proprietary Name": "XOPENEX",
        "Dosage Form": "Inhalation Solution",
        "Strength": "1.25 mg/3 mL",
        "NDA Applicant Name": "Oak Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "08/2012"
    },
    {
        "id": "1109",
        "Proprietary Name": "XOPENEX HFA",
        "Dosage Form": "Aerosol, metered",
        "Strength": "45 mcg/actuation 45 mcg/actuation",
        "NDA Applicant Name": "Lupin Inc",
        "Date Authorized Generic Entered the Market": "10/2016"
    },
    {
        "id": "1110",
        "Proprietary Name": "XYREM",
        "Dosage Form": "Oral Solution",
        "Strength": ".5g/mL",
        "NDA Applicant Name": "Jazz Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "7/3/2023"
    },
    {
        "id": "1111",
        "Proprietary Name": "XYREM",
        "Dosage Form": "Oral Solution",
        "Strength": ".5g/mL",
        "NDA Applicant Name": "Jazz Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "1/3/2023"
    },
    {
        "id": "1112",
        "Proprietary Name": "YASMIN",
        "Dosage Form": "Tablets",
        "Strength": "3 mg; 0.03 mg",
        "NDA Applicant Name": "Bayer HealthCare Pharmaceuticals Inc.",
        "Date Authorized Generic Entered the Market": "05/09/2008"
    },
    {
        "id": "1113",
        "Proprietary Name": "ZANAFLEX",
        "Dosage Form": "Capsule",
        "Strength": "6 mg",
        "NDA Applicant Name": "Covis Pharma GmbH",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "1114",
        "Proprietary Name": "ZANAFLEX",
        "Dosage Form": "Capsule",
        "Strength": "4 mg",
        "NDA Applicant Name": "Covis Pharma GmbH",
        "Date Authorized Generic Entered the Market": "10/2011"
    },
    {
        "id": "1115",
        "Proprietary Name": "ZARONTIN",
        "Dosage Form": "Capsules",
        "Strength": "250 mg",
        "NDA Applicant Name": "Parke-Davis Division of Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "10/12/2015"
    },
    {
        "id": "1116",
        "Proprietary Name": "ZAROXOLYN",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "1117",
        "Proprietary Name": "ZAROXOLYN",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "10/2018"
    },
    {
        "id": "1118",
        "Proprietary Name": "ZAROXOLYN",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Lannett Company, Inc.",
        "Date Authorized Generic Entered the Market": "11/2002 - 10/2003"
    },
    {
        "id": "1119",
        "Proprietary Name": "ZAVESCA",
        "Dosage Form": "Capsules",
        "Strength": "100 mg",
        "NDA Applicant Name": "Actelion Pharmaceuticals Ltd.",
        "Date Authorized Generic Entered the Market": "04/2018"
    },
    {
        "id": "1120",
        "Proprietary Name": "ZEBETA",
        "Dosage Form": "Tablets",
        "Strength": "5 mg",
        "NDA Applicant Name": "Lederle Laboratories",
        "Date Authorized Generic Entered the Market": "08/2000 - 08/2001"
    },
    {
        "id": "1121",
        "Proprietary Name": "ZEBETA",
        "Dosage Form": "Tablets",
        "Strength": "10 mg",
        "NDA Applicant Name": "Lederle Laboratories",
        "Date Authorized Generic Entered the Market": "08/2000 - 08/2001"
    },
    {
        "id": "1122",
        "Proprietary Name": "ZEGERID",
        "Dosage Form": "Capsules",
        "Strength": "20 mg/1100 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "02/27/2006"
    },
    {
        "id": "1123",
        "Proprietary Name": "ZEGERID",
        "Dosage Form": "Capsules",
        "Strength": "40 mg/1100 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "02/27/2006"
    },
    {
        "id": "1124",
        "Proprietary Name": "ZEGERID",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "20 mg/1680 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "1125",
        "Proprietary Name": "ZEGERID",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "40 mg/1680 mg",
        "NDA Applicant Name": "Salix Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "06/2014"
    },
    {
        "id": "1126",
        "Proprietary Name": "ZEMPLAR",
        "Dosage Form": "Capsules",
        "Strength": "1 mcg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "03/2014"
    },
    {
        "id": "1127",
        "Proprietary Name": "ZEMPLAR",
        "Dosage Form": "Capsules",
        "Strength": "2 mcg",
        "NDA Applicant Name": "AbbVie Inc.",
        "Date Authorized Generic Entered the Market": "03/2014"
    },
    {
        "id": "1128",
        "Proprietary Name": "ZENPEP",
        "Dosage Form": "Delayed Release Capsules",
        "Strength": "5000 lipase USP units",
        "NDA Applicant Name": "Eurand Pharmaceuticals, Ltd.",
        "Date Authorized Generic Entered the Market": "12/2/2009"
    },
    {
        "id": "1129",
        "Proprietary Name": "ZIAC",
        "Dosage Form": "Tablets",
        "Strength": "2.5 mg; 6.25 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "1130",
        "Proprietary Name": "ZIAC",
        "Dosage Form": "Tablets",
        "Strength": "5 mg; 6.25 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "1131",
        "Proprietary Name": "ZIAC",
        "Dosage Form": "Tablets",
        "Strength": "10 mg; 6.25 mg",
        "NDA Applicant Name": "Teva Branded Pharmaceutical Products R&D, Inc.",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "1132",
        "Proprietary Name": "ZIANA",
        "Dosage Form": "Gel",
        "Strength": "1.2% and 0.025%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "09/2020"
    },
    {
        "id": "1133",
        "Proprietary Name": "ZIOPTAN",
        "Dosage Form": "Sterile Ophthalmic Solution",
        "Strength": "0.0015%",
        "NDA Applicant Name": "Thea Pharma Inc.",
        "Date Authorized Generic Entered the Market": "11/18/2022"
    },
    {
        "id": "1134",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "300 mg (15 mL when mixed)",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "02/01/2005"
    },
    {
        "id": "1135",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "600 mg (15 mL when mixed)",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "02/1/2005"
    },
    {
        "id": "1136",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "900 mg (22.5 mL when mixed)",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "02/01/2005"
    },
    {
        "id": "1137",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "1 gram (single dose packet)",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "2/1/2005"
    },
    {
        "id": "1138",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Powder for Oral Suspension",
        "Strength": "1200 mg (30 mL when mixed)",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "02/01/2005"
    },
    {
        "id": "1139",
        "Proprietary Name": "ZITHROMAX",
        "Dosage Form": "Tablets",
        "Strength": "250 mg",
        "NDA Applicant Name": "Pfizer Inc.",
        "Date Authorized Generic Entered the Market": "02/01/2005"
    },
    {
        "id": "1140",
        "Proprietary Name": "ZOLOFT",
        "Dosage Form": "Oral Solution, Concentrate",
        "Strength": "20 mg/mL",
        "NDA Applicant Name": "Viatris Specialty LLC",
        "Date Authorized Generic Entered the Market": "03/20/2006"
    },
    {
        "id": "1141",
        "Proprietary Name": "ZOMIG",
        "Dosage Form": "Nasal Spray",
        "Strength": "5 mg",
        "NDA Applicant Name": "Amneal Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "07/15/2024"
    },
    {
        "id": "1142",
        "Proprietary Name": "ZOMIG",
        "Dosage Form": "Nasal Spray",
        "Strength": "2.5 mg",
        "NDA Applicant Name": "Amneal Pharmaceuticals LLC",
        "Date Authorized Generic Entered the Market": "07/15/2024"
    },
    {
        "id": "1143",
        "Proprietary Name": "ZONALON and PRUDOXIN",
        "Dosage Form": "Cream",
        "Strength": "5%",
        "NDA Applicant Name": "Mylan Pharmaceuticals, Inc.",
        "Date Authorized Generic Entered the Market": "01/2019"
    },
    {
        "id": "1144",
        "Proprietary Name": "ZORIVAX",
        "Dosage Form": "Cream",
        "Strength": "5%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/2019"
    },
    {
        "id": "1145",
        "Proprietary Name": "ZOVIRAX",
        "Dosage Form": "Ointment",
        "Strength": "5%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "04/2014"
    },
    {
        "id": "1146",
        "Proprietary Name": "ZYCLARA",
        "Dosage Form": "Cream",
        "Strength": "3.75%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "07/2020"
    },
    {
        "id": "1147",
        "Proprietary Name": "ZYCLARA",
        "Dosage Form": "Cream",
        "Strength": "3.75%",
        "NDA Applicant Name": "Bausch Health US, LLC",
        "Date Authorized Generic Entered the Market": "08/2018"
    },
    {
        "id": "1148",
        "Proprietary Name": "ZYLOPRIM",
        "Dosage Form": "Tablet",
        "Strength": "300 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "11/17/2022"
    },
    {
        "id": "1149",
        "Proprietary Name": "ZYLOPRIM",
        "Dosage Form": "Tablets",
        "Strength": "200 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "11/17/2022"
    },
    {
        "id": "1150",
        "Proprietary Name": "ZYLOPRIM",
        "Dosage Form": "Tablets",
        "Strength": "100 mg",
        "NDA Applicant Name": "Casper Pharma LLC",
        "Date Authorized Generic Entered the Market": "11/17/2022"
    },
    {
        "id": "1151",
        "Proprietary Name": "ZYMAXID",
        "Dosage Form": "Ophthalmic Solution",
        "Strength": "0.5 %",
        "NDA Applicant Name": "Allergan Sales, LLC",
        "Date Authorized Generic Entered the Market": "04/2015"
    },
    {
        "id": "1152",
        "Proprietary Name": "ZYVOX",
        "Dosage Form": "Oral Suspension",
        "Strength": "100 mg/5 mL",
        "NDA Applicant Name": "Pharmacia and Upjohn Company",
        "Date Authorized Generic Entered the Market": "12/2015"
    },
    {
        "id": "1153",
        "Proprietary Name": "ZYVOX",
        "Dosage Form": "Tablets",
        "Strength": "600 mg",
        "NDA Applicant Name": "Pharmacia and Upjohn LLC",
        "Date Authorized Generic Entered the Market": "12/2015"
    }
]